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Abstract
Mediterranean diet and the metabolic syndrome
Background: The metabolic syndrome refers to a clustering of risk factors including 
abdominal obesity, hyperglycaemia, low HDL-cholesterol, hypertriglyceridaemia, 
and hypertension and it is a risk factor for diabetes mellitus type 2 and cardiovascular 
disease. In this thesis we studied whether a Mediterranean diet favourably affects the 
metabolic syndrome.
Methods: We assessed the association between a Mediterranean diet and the metabolic 
syndrome in apparently healthy elderly European subjects (SENECA study) and in 
a Dutch study population that was oversampled with subjects with impaired glucose 
tolerance or diabetes mellitus type 2 (CoDAM study). In addition, we conducted a 
controlled-feeding trial to compare the effects of replacing a high saturated fatty acids 
(SFA) diet with a high monounsaturated fatty acids (MUFA) diet or a Mediterranean 
diet on characteristics of the metabolic syndrome: HDL-cholesterol, triglycerides and 
glucose metabolism (glucose concentration and insulin sensitivity).
Results: In both the SENECA study and the feeding trial we find support for the 
hypothesis that a Mediterranean diet has a beneficial effect on two characteristics of 
the metabolic syndrome, namely HDL-cholesterol and triglyceride concentrations. 
In addition, the findings of the SENECA study suggested that subjects with good 
adherence to a Mediterranean diet had a lower prevalence of the metabolic syndrome 
(prevalence ratio 0.81, 95%CI 0.65; 1.03) and a smaller waist circumference (-1.1 cm, 
95%CI -2.4; 0.3) than subjects with poor adherence. In the CoDAM study, we did not 
find these associations. In none of our studies we found support for the hypothesis 
that a Mediterranean diet has a beneficial effect on glucose concentration, insulin 
sensitivity or blood pressure.
Conclusion: This thesis finds support for a beneficial effect on two out of five 
characteristics of the metabolic syndrome and also suggests a beneficial effect on a 
third characteristic (abdominal obesity). We therefore conclude that a Mediterranean 
diet may help to prevent the metabolic syndrome and consequently diabetes mellitus 
type 2 and cardiovascular disease. 
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The metabolic syndrome
The number of people with diabetes mellitus or cardiovascular disease is high due 
to the ageing of population and the obesity epidemic. Diabetes mellitus type 2 and 
cardiovascular disease have a number of risk factors in common: low HDL-cholesterol 
concentrations, hypertriglyceridaemia, obesity, hyperglycaemia and hypertension. 
These risk factors tend to cluster in the same individual. Gerald Reaven was the first 
to suggest that these risk factors are related to each other. He called this clustering of 
risk factors “syndrome X” and proposed that insulin resistance was the underlying 
mechanism of this syndrome [1]. After Reaven had launched the idea of the syndrome, 
the name of the clustering of risk factors has changed from syndrome X to become 
known as the metabolic syndrome. According to a meta-analysis of 37 studies, it has 
been shown to be associated with an increased risk of cardiovascular events and death 
(RR 1.78, 95%CI 1.58; 2.00) [2]. In addition, the metabolic syndrome has been shown 
to be associated with an increased risk of diabetes mellitus type 2 (RR 3.57, 95%CI 
2.83; 4.50) [3]. 
Definition of the metabolic syndrome
The metabolic syndrome refers to a clustering of risk factors rather than to a single 
disease, and there is currently no consensus about the definition. As a consequence, 
several organizations have developed their own working definitions [4-8]. Two 
definitions emphasized insulin resistance in their working definition [4, 5] and one 
definition emphasized abdominal obesity [8]. Although these definitions differ to 
some extent in the risk factors included and cut-off values used for specific risk 
factors, all definitions include low HDL-cholesterol, hypertriglyceridaemia, a measure 
of (abdominal) obesity, hyperglycaemia and hypertension. In this thesis, we used 
the definition of the National Cholesterol Education Program (NCEP) because this 
definition does not suggest an underlying cause of the metabolic syndrome and it 
is the most widely used definition in the literature [9]. It is based on criteria that 
are easily applicable in daily practice. According to this definition, the metabolic 
syndrome is present if at least three out of five characteristics are present: low HDL-
cholesterol concentration, hypertriglyceridaemia, abdominal obesity, hyperglycaemia, 
and hypertension [6]. In 2005, this NCEP definition was modified by including drug 
treatment for four out of the five characteristics (all but abdominal obesity) and by 
lowering the cut-off value for hyperglycaemia [10] (Table 1.1). In this thesis, we used 
the most recent 2005 definition if data about drug treatment were available, otherwise 
we used the 2001 definition.
Prevalence of the metabolic syndrome 
Worldwide, the prevalence of the metabolic syndrome is high. In North and South 
America, Europe and India, the prevalence of the metabolic syndrome is at least 25% 
[11]. The prevalence in Southeast Asia is currently below 20% but it is expected to rise 
with the ageing of the population [11]. In the Netherlands, the prevalence according 
to the NCEP 2001 definition was 26% in older men and 19% in older women (50-75 
years) [12]. However, the prevalence according to the NCEP definition in a younger 
Dutch population had not been published previously.
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Pathophysiology 
The different characteristics and cut-off values used in the working definition of the 
metabolic syndrome indicate that there is no consensus yet about its pathophysiology. 
Some researchers suggested that abdominal obesity plays a central role [8] but others 
suggested that insulin resistance is the central component [1]. 
Insulin action and abdominal obesity
The hormone insulin regulates glucose homeostasis through stimulation of glucose 
uptake in muscle tissue and adipose tissue, suppression of glucose production in the liver 
and of lipid release from adipose tissue (Figure 1.1a). Although muscle tissue accounts 
for the main part of glucose uptake, also adipose tissue is important in the regulation 
of insulin action [13, 14]. Adipose tissue does not only store lipids but also has an 
endocrine function. Adipocytes can produce and secrete adipokines. In overweight or 
obese subjects abnormal levels of adipokines are secreted, which impairs the action of 
insulin. This abnormal secretion is at least partly caused by chronic inflammation within 
the adipose tissue. Target tissues and organs become less sensitive to insulin, which leads 
to insulin resistance.
Insulin resistance
Impairment of insulin action increases plasma glucose concentration because glucose 
uptake in muscle tissue and adipose tissue is reduced and glucose production in the 
liver is increased (Figure 1.1b). This increase in glucose concentration stimulates insulin 
production in the β-cells of the pancreas, to reduce plasma glucose concentrations [16]. 
Chapter 1
Table 1.1  Characteristics of the metabolic syndrome according to the National Cholesterol 
Education Program (NCEP) Adult Treatment Panel III
Characteristics of the
metabolic syndrome
NCEP (2001) NCEP (2005)
Low HDL-cholesterol <1.04 mmol/L (men)
<1.29 mmol/L (women)
<1.04 mmol/L (men)
<1.29 mmol/L (women)
Or drug treatment for low HDL-cholesterol
Hypertriglyceridaemia ≥1.7 mmol/L ≥1.7 mmol/L
Or drug treatment for hypertriglyceridaemia
Abdominal obesity Waist circumference
>102 cm (men) 
>88 cm (women)
Waist circumference
>102 cm (men) 
>88 cm (women)
Hyperglycaemia ≥6.1 mmol/L ≥5.6 mmol/L
Or drug treatment for hyperglycaemia
Hypertension ≥130/≥85 mmHg ≥130/≥85 mmHg
Or drug treatment for hypertension
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When this compensation mechanism is no longer adequate, hyperglycaemia develops. 
The impairment of the action of insulin also results in the loss of the vasodilatory effect 
of insulin, which may lead to hypertension [17]. In addition, the impairment of the 
action of insulin increases lipid release from adipose tissue. The increase of free fatty 
acids results in the production of more triglyceride-rich VLDL in the liver [18]. High 
triglyceride-rich VLDL concentration in the blood increases the exchange of triglycerides 
from VLDL for cholesterol esters from HDL. This exchange is mediated by cholesteryl 
ester transfer protein and results in triglyceride-rich HDL. Triglyceride-rich HDL is a 
substrate for hepatic lipase and lipoprotein lipase, which hydrolyze the triglycerides 
resulting in a smaller lipid-poor HDL particle. Thus, impairment of the action of insulin 
increases lipid transport in the plasma, which is the driving force of elevated triglyceride 
concentrations and reduced HDL-cholesterol concentrations. 
Chapter 1
Figure 1.1  Physiological functions of insulin (a) and the consequences of insulin resistance 
(b). This figure is based on Olijhoek et al. [15] and was translated and modified with 
permission.
(a)
(b)
insulin
glucose production
vasodilatation glucose uptake
lipid release glucose uptake
fat tissue
blood vessels
liver
muscle tissue
_ +
++
_
5Introduction
Prevention of the metabolic syndrome
Underlying risk factors for the metabolic syndrome are physical inactivity and an 
unhealthy diet. These risk factors are modifiable, and therefore lifestyle changes should 
have prime emphasis in the management of the metabolic syndrome [10]. In the 
Netherlands, a multidisciplinary guideline for cardiovascular risk management has 
been developed [19, 20]. This guideline does not specifically provide lifestyle advice 
for persons with the metabolic syndrome, but provides advice for persons having a 
more than 5% risk to die from cardiovascular disease in the next 10 years. This lifestyle 
advice comprises reducing obesity, increasing physical activity, stopping smoking, and 
eating a healthy diet. The recommended healthy diet is based on the most recent dietary 
guidelines of the Dutch Health Council [21] and contains less than 10% of total energy 
intake (energy-%) of saturated fatty acids (SFA), less than 1 energy-% of trans fatty acids, 
at least once a week fatty fish, minimal 200 g vegetables and 2 pieces of fruit daily, salt 
consumption of a maximum of 6g/day and a maximum alcohol consumption of 2 glasses/
day for women and 3 glasses/day for men. This recommended diet has many similarities 
with a Mediterranean diet, which has been associated with a reduced risk of mortality 
[22] and might have favourable effects on the metabolic syndrome. 
A Mediterranean diet
A Mediterranean diet refers to a dietary pattern as consumed in countries of the 
Mediterranean region during the early 1960s. The term Mediterranean diet suggests 
that there is one diet for all countries of the Mediterranean region. However, many 
differences in diet between Mediterranean countries exist [23]. Therefore, there is not 
just one Mediterranean diet but many Mediterranean diets. Because of this, the term 
“a Mediterranean diet” or “a Mediterranean type of diet” is more appropriate than “the 
Mediterranean diet”. Common characteristics of a Mediterranean diet are use of olive 
oil as the main added lipid, abundant use of plant foods (fruits, vegetables, cereals, 
legumes, nuts, and seeds), moderate intake of fish and wine, and low to moderate 
consumption of dairy products and meat and poultry [24-26]. 
A Mediterranean diet and the metabolic syndrome
Observational studies have shown that a Mediterranean diet was associated with the 
metabolic syndrome in Southern Europe. A Mediterranean diet was inversely associated 
with the prevalence of the metabolic syndrome in Greek adults [27] and with the 
incidence of the syndrome in young Spanish subjects [28]. In Spanish adults living on 
the Canary Islands, no association between a Mediterranean diet and the prevalence 
of the metabolic syndrome was shown [29], although a favourable association with 
some of the characteristics of the metabolic syndrome was observed. No information 
is available about the association between a Mediterranean diet and the metabolic 
syndrome in other parts of Europe.
Two intervention studies in subjects at high cardiovascular risk have shown that a 
Mediterranean diet improves insulin sensitivity [30, 31]. Such an effect could not 
be demonstrated in healthy subjects [32]. The results of these intervention studies 
suggest that a Mediterranean diet may be more effective to improve insulin sensitivity 
Chapter 1
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in high-risk subjects than in healthy subjects. However, there is limited evidence 
from observational studies underpinning this suggestion. The only observational 
study reported so far, found an association between a Mediterranean diet and insulin 
sensitivity in healthy subjects with normal glucose tolerance but not in high-risk 
subjects with impaired glucose regulation or with diabetes mellitus type 2 [33]. As these 
findings contradict the results of the intervention studies, they need replication.
A Mediterranean diet; is it the effect of monounsaturated fatty acids? 
A Mediterranean diet contains several components that potentially have a beneficial 
effect on characteristics of the metabolic syndrome. For example, olive oil, nuts, fish, 
dietary fibre, and alcohol may favourably affect serum lipids or insulin sensitivity [34-
38]. The high olive oil consumption in a Mediterranean diet is particularly interesting, 
because it is expected to have a beneficial effect on serum lipids as well as on insulin 
sensitivity. Olive oil is rich in monounsaturated fatty acids (MUFA) and replacing SFA 
with MUFA in the diet reduces total cholesterol, LDL-cholesterol, and triglyceride 
concentrations [39]. Replacing SFA with MUFA also increased insulin sensitivity in 
two intervention studies [40, 41]. The two intervention studies that showed that a 
Mediterranean diet is able to improve insulin sensitivity also observed improvements 
in serum lipids [30, 31]. However, these studies were not able to determine whether 
the effects of a Mediterranean diet were due to the high MUFA content of the diet or 
to the cumulative effect of the Mediterranean diet components. 
Outline of the thesis
The main objective of this thesis was to study whether a Mediterranean diet affects 
the metabolic syndrome. In chapter 2, the prevalence of the metabolic syndrome in 
the Netherlands was estimated. We studied whether a Mediterranean diet is associated 
with the metabolic syndrome in two observational studies. In chapter 3, the association 
between a Mediterranean diet and the metabolic syndrome in a study among European 
elderly subjects is described. In chapter 4, the association between a Mediterranean diet 
and markers of glucose metabolism and the metabolic syndrome in healthy and high-
risk subjects is described. A controlled-feeding trial was carried out to study the effects 
of a Mediterranean diet on characteristics of the metabolic syndrome. In this trial, the 
effects of a Mediterranean diet on serum lipids and insulin sensitivity were compared 
with the effects of a high MUFA-diet and of a high SFA-diet. The results of this trial 
are presented in chapters 5 and 6. In chapter 7, our findings will be summarised and 
critically discussed in view of the used methodology and findings from literature. 
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Abstract
Objective: To estimate the prevalence of the metabolic syndrome in the Netherlands in 
two populations in the age category 28-59 years and to compare this with the prevalence 
of hypercholesterolaemia in these populations.
Design: Descriptive.
Methods: Data from two Dutch population based studies were used: the ‘Monitoring risk 
factors and health in the Netherlands’ (MORGEN) study (1993-1995) and the ‘Prevention 
of renal and vascular end-stage disease’ (PREVEND) study (1998-1999). Subjects 
were identified as having the metabolic syndrome when they had at least three of the 
following five criteria according to the guideline of the ‘National Cholesterol Education 
Program’, ‘Adult treatment panel III’ (NCEP-2001): hyperglycaemia, low HDL-cholesterol 
concentration, hypertriglyceridaemia, hypertension or abdominal obesity. Final estimates 
were weighed according to the age- and sex distribution of the Dutch population during 
these survey years based on figures of the Dutch Central Bureau of Statistics.
Results: On average, the prevalence of the metabolic syndrome was 14%; 19% in men 
and 12% in women in the MORGEN study, and 16% and 10% in men and women in the 
PREVEND study. The prevalence in subjects below 40 years of age was 12% for men and 
5% for women. The prevalence increased considerably with age. Among subjects with 
both abdominal obesity and hypertension the prevalence was 68%. Among subjects with 
‘hypertriglyceridaemic waist’ the prevalence was 94%. The prevalence of the metabolic 
syndrome showed little overlap with the prevalence of hypercholesterolaemia (≥6.5 
mmol/l). In total, 26% of the subjects had either the metabolic syndrome or high total 
cholesterol concentrations.
Conclusion: Approximately one million Dutch adults below 60 years of age had the 
metabolic syndrome in the 1990s. Based on the total prevalence of the metabolic syndrome 
and hypercholesterolaemia, one quarter of the Dutch population younger than 60 years 
runs an increased risk of cardiovascular disease and diabetes mellitus type 2.
Introduction
The metabolic syndrome (also known as insulin-resistance syndrome, dysmetabolic 
syndrome or syndrome X), is an important risk factor for diabetes mellitus type 2 and 
cardiovascular disease [3, 12, 42-45]. The metabolic syndrome refers to a cluster of risk 
factors such as glucose tolerance, hypertension, obesity and dyslipidaemia.
In recent years, several definitions have been formulated for the metabolic syndrome, 
and they were recently summarised in this journal [15]. The definition formulated by 
the National Cholesterol Education Program, Adult Treatment Panel III (NCEP 2001) 
is widely used and is based on a number of diagnostic criteria that are easy to apply 
in clinical practice, such as blood pressure, waist circumference and fasting plasma 
concentrations of glucose, HDL-cholesterol and triglycerides [6]. The metabolic 
syndrome is diagnosed when three or more of the five criteria show abnormalities. 
This method does not emphasize any particular criterion. Neither does it suggest an 
underlying cause of the metabolic syndrome.
Particularly after the metabolic syndrome was included in the NCEP 2001 guidelines, 
the cluster of risk factors received a great deal of attention in the biomedical literature. 
Recently, however, its clinical relevance has been questioned [46]. For example, 
the metabolic syndrome appears to be a less reliable predictor of cardiovascular 
disease than the Framingham risk score [3, 47]. Although the definition of the 
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metabolic syndrome partly corresponds to the Framingham risk score and also to 
the SCORE risk function in the new ‘clinical practice guideline for cardiovascular 
risk management in the Netherlands’[19], there are also differences. These relate 
mainly to the risk factors hypercholesterolaemia, age and smoking. Greater insight 
into the total size of the population with a high risk of cardiovascular disease can 
therefore be obtained by comparing the prevalence of the metabolic syndrome with 
that of hypercholesterolaemia. A good estimate of the prevalence of the metabolic 
syndrome provides information not only on the number of persons with a high risk of 
cardiovascular disease, but also on the risk of diabetes mellitus type 2 and the possible 
implications for public health. To a lesser extent, this is true for the other risk scores 
mentioned, partly because abdominal obesity is not included.
In 1990, the prevalence of the metabolic syndrome, when defined according to the 
NCEP-2001 criteria, was 26% in men and 19% in women between 50 and 74 years of age 
(the ‘Hoorn Study’) [12]. In the period 1993-1995, prevalence according to older criteria 
[4, 5] varied between 3% in women of 20-39 years of age and 33% in men of 55 years 
and older [48]. In this study we assessed the prevalence of the metabolic syndrome, 
defined according to the NCEP-2001 criteria, in the age category 28-59 years in the 
most recent available representative random samples of the Dutch population. The 
samples dated from the period 1993-1999. We assessed the to which extent the non-
biochemical parameters (abdominal obesity and hypertension) and the combination 
of hypertriglyceridaemia and abdominal obesity (also known as ‘hypertriglyceridaemic 
waist’) [49] are good indicators of the metabolic syndrome. Finally, we studied the 
overlap with the prevalence of hypercholesterolaemia.
Subjects and methods 
Study population and weighting 
The study population comprised the participants in the project ‘Monitoring of risk 
factors and health in the Netherlands’ (MORGEN study) by the National Institute for 
Public Health and the Environment (RIVM) and the participants in the ‘Prevention of 
Renal and Vascular End-stage Disease’ (PREVEND) study by the University Medical 
Center Groningen (UMCG).
In the MORGEN study, in the period 1993-1997, a representative random sample 
of men and women between 20 and 59 years of age from the cities of Maastricht, 
Doetinchem and Amsterdam was examined each year [50, 51]. After the study, the 
fasting insulin and triglyceride concentrations were measured in 1378 stored blood 
samples taken in the period 1993-1995. For these additional measurements, an equal 
number of blood samples were selected by gender and 5-year age stratum.
The PREVEND study was a cohort study, for which the first screening took place in 
1998 and 1999 [52]. All residents of the city of Groningen between 28 and 75 years of 
age were invited to take part in the screening. Respondents submitted a morning urine 
sample in which albumin secretion was measured. All persons with a high-normal 
albumin secretion (10-20 mg/l) or microalbuminuria (albumin secretion 20-200 mg/l) 
were then invited to take part in the study. A random sample was also taken among 
Chapter 2 
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the people with non-abnormal albumin secretion. In the final study population, 
these groups were combined in proportion to the frequency of albuminuria (high, 
high-normal, normal) by means of weighting factors. Therefore, the data reflected 
the screened PREVEND population.
In order to combine the results of the two studies properly, the interval 28-59 years 
was taken as the age threshold for the study population of both the MORGEN study 
and the PREVEND study. Participants from whom fasting blood samples were taken, 
and in whom all criteria of the metabolic syndrome were measured, were included 
in the present data analysis; 1125 participants for the MORGEN study and 5508 
Chapter 2 
Table 2.1  Characteristics of participants of the MORGEN and the PREVEND study in men 
and women, weighted according to the age distribution of the Dutch population in the 
year of the study (respectively 1 January 1994 and 1 January 1998)
MORGEN= ‘Monitoring of risk factors and health in the Netherlands’ [50, 51]; PREVEND= ‘Prevention of Renal 
and Vascular End-stage Disease’ [52].
1 Assessed by use of diabetes medication or diet.
2 The data from the PREVEND study were also weighted by study design.
Mean (sd)
men women
MORGEN study (1993-1995)
N 583 542
Age, years 41.9 (8.8) 42.0 (9.0)
Glucose, mmol/L 5.6 (1.1) 5.2 (0.8)
Total cholesterol, mmol/L 5.58 (1.10) 5.47 (1.18)
HDL-cholesterol, mmol/L 1.18 (0.30) 1.47 (0.37)
Triglyceride, mmol/L 1.46 (1.37) 1.03 (0.64)
Systolic blood pressure, mmHg 123.9 (15.5) 116.3 (16.1)
Diastolic blood pressure, mmHg 80.9 (10.0) 76.1 (10.3)
Body mass index, kg/m2 25.9 (3.7) 25.2 (4.4)
Waist circumference, cm 93.7 (10.7) 81.9 (11.6)
Diabetes mellitus1, % 1 0
Use of antihypertensives, % 3.8 3.4
PREVEND study2 (1998-1999)
N 2575 2933
Age, years 42.2 (9.3) 42.3 (8.5)
Glucose, mmol/L 4.9 (1.0) 4.6 (0.9)
Total cholesterol, mmol/L 5.57 (1.21) 5.38 (1.03)
HDL-cholesterol, mmol/L 1.18 (0.33) 1.55 (0.39)
Triglyceride, mmol/L 1.55 (1.33) 1.13 (0.64)
Systolic blood pressure, mmHg 128.0 (14.4) 117.7 (14.6)
Diastolic blood pressure, mmHg 74.1 (9.0) 68.9 (7.8)
Body mass index, kg/m2 25.7 (3.7) 25.2 (4.3)
Waist circumference, cm 91.4 (11.0) 80.4 (11.0)
Diabetes mellitus1, % 0.3 0.7
Use of antihypertensives, % 4.0 5.5
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participants for the PREVEND study. There was no exclusion on the basis of medical 
history (e.g. diabetes mellitus). An overview of the characteristics of the participants 
can be found in (Table 2.1). 
Measurements and definitions
Both studies used a standardized questionnaire that included information about 
age, diabetes, and use of medication (e.g. blood-glucose-lowering medication, 
antihypertensives and lipid-lowering medication). Height and weight were measured 
and the body mass index (in kg/m2) was calculated. Waist circumference was measured 
halfway between the lower rib and the crest of the pelvis. In the MORGEN study, 
blood pressure was measured twice with a random-zero sphygmomanometer while 
the participant was in a seated position. The average of the two measurements was 
used in the calculations. In the PREVEND study, the participants’ blood pressure 
was measured continuously for 10 minutes on two different days, when lying down 
(automatic Dinamap XL Model 9300; Johnson-Johnson Medical, Inc., Tampa, FL, U.S.). 
The average of the final two measurements was used in the calculations. 
In the MORGEN study, concentrations of plasma glucose, total and HDL-cholesterol 
were measured by the Central Clinical Chemical Laboratory of the Erasmus Medical 
Center, Rotterdam, using standardized enzymatic methods. Triglyceride concentration 
was measured enzymatically using an Abbott Spectrum clinical analyser (Abbott 
Laboratories, Chicago, IL, U.S.) by the chemical laboratory of the Division of Human 
Nutrition, Wageningen University. In the PREVEND study, glucose, triglyceride, 
total and HDL-cholesterol concentrations were measured on site using the Kodak 
Ektachem ‘dry chemistry’ method (Eastman Kodak, Rochester, NY, U.S.). Blood-
glucose concentrations were converted into equivalent plasma-glucose concentrations 
according to the Passing and Bablok method ((1.125 × blood glucose concentration) 
– 0.4375).
As mentioned, according to the NCEP 2001 definition, the metabolic syndrome is 
present when at least three of the following five criteria are met: hyperglycaemia 
(fasting glucose concentration ≥6.1 mmol/l), HDL-cholesterol concentration <1.04 
mmol/l for men and <1.29 mmol/l for women, hypertriglyceridaemia (triglyceride 
concentration ≥1.7mmol/l), hypertension (systolic blood pressure ≥130 mmHg and/
or diastolic blood pressure ≥85 mmHg, or the use of antihypertensives), abdominal 
obesity (waist circumference >102 cm for men and >88 cm for women) [6]. The 
criterion for hypercholesteraemia was a total cholesterol concentration ≥6.5 mmol/l, 
as recommended in the new ‘clinical practice guideline for cardiovascular risk 
management in the Netherlands’.
Statistics
The results were weighted according to age (by 5-year age groups) and sex distribution 
of the Dutch population, according to the data of the Dutch Central Bureau of Statistics 
(CBS) in the year of the study (1 January 1994 for the MORGEN study and 1 January 
1998 for the PREVEND study) and using the computer programme SAS version 9.0 
(SAS Institute Inc., Cary, NC, U.S.). The data from the PREVEND study were weighted 
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in proportion to the frequency of microalbuminuria, high-normal and normal urinary 
albumin concentration in the screened population, so that the final data reflected the 
screened population.
The prevalences observed in this study were extrapolated to the number of persons 
in the Dutch population who could be diagnosed with ‘the metabolic syndrome’ in 
the same year. Differences between men and women with regard to the prevalences 
of the metabolic syndrome and its individual criteria were tested using the χ2 test. 
The Cochrane-Armitage trend test, which is available in the SAS software, was used 
to test the prevalence of the metabolic syndrome by age category.
Results
Metabolic syndrome
The characteristics of the study population are shown in Table 2.1. The prevalence of the 
metabolic syndrome was 19% in the MORGEN study and 16% in the PREVEND study 
for men, and 12% and 10% respectively for women (Table 2.2). When the prevalences 
Chapter 2 
Figure 2.1  Prevalence of the metabolic syndrome according to the definition of the National 
Cholesterol Education Program (NCEP 2001) in men and women by age category in two 
studies (      :‘Monitoring of risk factors and health in the Netherlands’ (MORGEN study) 
(50, 51) and      :‘Prevention of Renal and Vascular End-stage Disease’ (PREVEND study) 
(52)), weighted according to the age distribution of the Dutch population in the year of 
the study (respectively 1 January 1994 and 1 January 1998). The vertical line bars indicate 
95%-confidence intervals.
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from these two studies were extrapolated to the Dutch population, this corresponded to 
approximately 1 million persons with the metabolic syndrome in the 1990s. Prevalence 
increased sharply with age (Figure 2.1). Testing revealed a significant age-related 
trend: for men this was p=0.001 and p<0.001 respectively in the MORGEN study and 
the PREVEND study, and for women p<0.0001 and p<0.0001. The prevalence of the 
metabolic syndrome was already considerable in persons under 40 years of age: 12% 
in men compared with 5% in women. Above the age of 50, the prevalence in men and 
women was comparably high (20-25%). 
More than half the number of men with abdominal obesity had the metabolic syndrome 
(MORGEN study: 58%; PREVEND study: 64%) (Table 2.3). The prevalence among 
women with abdominal obesity was slightly lower: 44 and 39% respectively in the 
MORGEN study and the PREVEND study. The prevalence in men and women with 
abdominal obesity as well as hypertension was 68%.
Separated into the three risk factors that are part of the metabolic syndrome and are 
measured in plasma, the prevalence of the metabolic syndrome was approximately 
54% for persons with hypertriglyceridaemia and approximately 41% for men and 30% 
for women with a low HDL-cholesterol concentration. In contrast to the other results, 
a considerable difference was found between the two studies with regard to persons 
with hyperglycaemia; the prevalence of the metabolic syndrome was very high in the 
PREVEND study. For the group of participants with hypertriglyceridaemia as well as 
abdominal obesity, the prevalence of the metabolic syndrome varied between 86% 
Table 2.2  Prevalence of the metabolic syndrome and its characteristics according to the 
definition of the National Cholesterol Education Program (NCEP 2001) in men and women 
aged between 28 and 60 years in two studies (MORGEN study and PREVEND study), 
weighted according to the age distribution of the Dutch population in the year of the study 
(respectively 1 January 1994 and 1 January 1998)
MORGEN= ‘Monitoring of risk factors and health in the Netherlands’ [50, 51]; PREVEND= ‘Prevention of Renal 
and Vascular End-stage Disease’ [52].
1 The data from the PREVEND study were also weighted by study design.
2 Significant difference between men and women (p < 0.001).
3 Including use of antihypertensives.
Prevalence in % (95%-confidence interval)
MORGEN study PREVEND study1
men 
N=583
women 
N=542
men
N=2575
women
N=2933
Metabolic syndrome (NCEP 2001) 19 (16-22) 12 (9-15)2 16 (15-17) 10 (9-11)2
Low HDL-cholesterol 34 (30-38) 33 (29-37) 36 (34-38) 28 (26-30)2
Hypertension3 42 (38-46) 26 (22-30)2 44 (42-46) 21 (20-22)2
Abdominal obesity 21 (18- 24) 23 (19-27) 13 (12-14) 23 (21-25)2
Hyperglycaemia 20 (17-23) 9 (7-11)2 5 (4-6) 3 (2-4)2
Hypertriglyceridaemia 24 (21-27) 13 (10-16)2 29 (27-31) 13 (12-14)2
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for women in the PREVEND study and 97% for men in the MORGEN study. The 
prevalence of hypercholesterolaemia (total cholesterol concentration ≥6.5 mmol/l) 
was on average 17% based on both studies; this was higher than the prevalence of the 
metabolic syndrome (average 14%). However, the overlap between the two risk groups 
was small. Both risk factors were present in 4% of the study population.
Hypercholesterolaemia
Of the participants, 13% had hypercholesterolaemia without the metabolic syndrome; 
9% had the metabolic syndrome without hypercholesterolaemia (results not shown). The 
total high-risk group based on the metabolic syndrome and/or hypercholesterolaemia 
accounted for 26% of the study population.
Discussion
This study indicates that, in the 1990s, the prevalence of the metabolic syndrome 
in Dutch adults under the age of 60 was 15-22% in men and 9-15% in women, 
i.e. approximately one million Dutch adults. Most of these adults did not have 
hypercholesterolaemia. Approximately one-quarter of persons below the age of 60 had 
a high risk on the basis of metabolic risk factors, including hypercholesterolaemia.
Another notable finding is the relatively high prevalence of the metabolic syndrome in 
men below the age of 40. We attempted to obtain as accurate an impression as possible 
of the Dutch population, and the MORGEN study was set up as a representative random 
Chapter 2 
MORGEN= ‘Monitoring of risk factors and health in the Netherlands’ [50, 51]; PREVEND= ‘Prevention of Renal 
and Vascular End-stage Disease’ [52].
1 The data from the PREVEND study were also weighted by study design.
2 Significant difference between men and women (p < 0.001).
3 Including use of antihypertensives.
Criteria of the metabolic syndrome Prevalence in % (95%-confidence interval)
MORGEN study PREVEND study1
men women men women
Low HDL-cholesterol 42 (35-49) 28 (21-35) 41 (38- 44) 30 (27-33)2
Hypertension3 33 (27-39) 32 (24-40) 33 (30-36) 36 (32-40)
Abdominal obesity 58 (49-67) 44 (35-53) 64 (59-69) 39 (35-43)2
Hyperglycaemia 48 (39-57) 44 (30-58) 70 (62-78) 82 (73-91)
Hypertriglyceridaemia 57 (49-65) 57 (45-69) 51 (48-54) 50 (47-57)
Abdominal obesity + hypertension3 64 (53-75) 67 (55-79) 75 (70-80) 69 (63-75)
Abdominal obesity + hypertriglyceridaemia 97 (92-100) 93 (84-100) 96 (93-99) 86 (81-91)2
Table 2.3  Prevalence of the metabolic syndrome according to the definition of the National 
Cholesterol Education Program (NCEP 2001) in subgroups of subjects who fulfilled one or 
two of the criteria of the metabolic syndrome: men and women aged between 28 and 60 
years in two studies (MORGEN study and PREVEND study), weighted according to the age 
distribution of the Dutch population in the year of the study (respectively 1 January 1994 
and 1 January 1998)
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sample of that population. Although the study population of the PREVEND study 
was over selected with persons with microalbuminuria, the weighting of the results 
to the study design makes the study population a good representation of the screened 
population. Because the results of the MORGEN study generally corresponded to 
those of the PREVEND study, these two studies together provide a good picture of 
the Dutch population in the 1990s. It was not possible to adjust for the fact that, on 
average, participants in scientific studies have a higher socioeconomic status and are 
therefore probably healthier than the general population [53].
In recent years there has been an increase in the number of people in the Netherlands 
who are overweight and take little exercise [54, 55], which means that an increase in 
the number of people with the metabolic syndrome can also be expected. However, 
in this study we observed no difference between the prevalence of the metabolic 
syndrome in the MORGEN study carried out in 1993-1995 and the prevalence in the 
PREVEND study carried out in 1998 and 1999. There was no great difference in the 
prevalence of the metabolic syndrome in the age category 50-74 years between the 
‘Hoorn Study’ from 1990, with prevalences of 26% in men and 19% in women [12] 
and the PREVEND study with prevalences of 24% and 26% respectively. This suggests 
in any case that prevalence did not change significantly during the 1990s.
In previous studies in Europe published in the early 1990s, in which the metabolic 
syndrome was defined according to WHO criteria, prevalence was found to be 15% in 
the population of 30-89 years of age [42], and 7-36% in men and 5-22% in women aged 
40-54 years [48]. As in the present study, the prevalence of the metabolic syndrome 
in these European studies was higher in men than in women, and increased sharply 
with age. However, when assessing gender differences, the age of the study populations 
can have a distorting effect. In our study, the prevalence of the metabolic syndrome in 
women increased sharply with age, and the difference in men and women was more 
prominent in the younger age categories than in the older age categories (Figure 2.1). 
This may be due to hormonal changes, given that the menopause is accompanied by 
an increase in abdominal fat deposit [56].
Doubts have been raised with regard to the value of the entity ‘metabolic syndrome’ 
in clinical practice [46]. Some studies have found that the metabolic syndrome has an 
added value in relation to existing risk factors in predicting the risk of cardiovascular 
disease [57]. However, other studies show no added value in relation to the Framingham 
risk score and have found that the number of risk factors provides more information 
in terms of predicting cardiovascular disease [12]. This assumes that, in practice, it is 
possible to measure all the separate risk factors, and that this will be done. However, 
the metabolic syndrome comprises more than the criteria of the definition alone, 
such as sub-chronic inflammation, small dense LDL and reduced clotting potential, 
which are not routinely measured [58]. In that case, the diagnosis of the metabolic 
syndrome can be seen as a simple means of recognising a more extensive cluster 
of risk factors [58]. Given the clustering that is also apparent in the Dutch study 
populations, it is clear that, in the case of individuals with one or two criteria of the 
metabolic syndrome, it is necessary to be alert to the presence of other risk factors. 
Our study showed that more than half of all men and approximately 40% of women 
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with abdominal obesity have at least two other criteria of the metabolic syndrome, 
and therefore the metabolic syndrome (Table 2.3). Approximately two-thirds of men 
and women with abdominal obesity as well as hypertension have at least one other 
criteria of the metabolic syndrome.
This study showed a high prevalence of the metabolic syndrome in Dutch adults below 
60 years of age, but there was little overlap with the diagnosis ‘hypercholesterolaemia’. 
In total, one-quarter of Dutch adults below the age of 60 have an increased risk of 
cardiovascular disease or diabetes mellitus type 2. This information is relevant for 
clinical practice and policy in terms of forecasting the demand for care, but also 
highlights the need for prevention (e.g. through lifestyle changes).
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Abstract
The relationship between a Mediterranean diet and the metabolic syndrome has 
been scarcely studied in elderly populations. We analysed the association between a 
Mediterranean diet and the metabolic syndrome and its characteristics in a European 
elderly population using baseline data of the Survey in Europe on Nutrition and the 
Elderly, a Concerted Action (SENECA).
The study population included 627 men and 631 women, aged between 70 and 76 
years of 10 European countries. Adherence to a Mediterranean diet was assessed by 
the Mediterranean diet score (MDS, range 0 through 9). All analyses were adjusted for 
study centre. Analyses on waist circumference were also adjusted for sex and physical 
activity. Although not statistically significant, elderly subjects with good adherence to a 
Mediterranean diet (MDS >4 (median)) had a lower prevalence of the metabolic syndrome 
(prevalence ratio 0.81, 95%CI 0.65; 1.03) and tended to have smaller waist circumference 
(-1.1 cm, 95%CI -2.4; 0.3) than elderly subjects with poor adherence. Good adherence to 
a Mediterranean diet was associated with higher HDL-cholesterol (0.05 mmol/L, 95%CI 
0.00; 0.10) and lower triglyceride concentrations (-0.12 mmol/L, 95%CI -0.24; 0.00) but 
not with measures of insulin sensitivity.
These results implicate that the prevalence of the metabolic syndrome is lower in elderly 
people with good adherence to a Mediterranean diet.
Introduction
A Mediterranean diet has been associated with reduction in mortality [22] and with 
several protective factors for cardiovascular disease [9]. The Mediterranean diet is 
characterized by use of olive oil as the main added lipid, abundant use of plant foods 
(fruits, vegetables, cereals, legumes, nuts, and seeds), moderate intake of fish and 
wine, and low to moderate consumption of dairy products and meat and poultry 
[24-26]. It was suggested that adoption of a Mediterranean diet may also prevent 
people from developing the metabolic syndrome [59]. This syndrome is a risk factor 
for cardiovascular disease and diabetes mellitus type 2 [3, 42, 43] and is present if 
at least three of five characteristics are present: low HDL-cholesterol concentration, 
hypertriglyceridaemia, abdominal obesity, hyperglycaemia, and hypertension [6]. 
Intervention studies in subjects at high cardiovascular risk showed that a Mediterranean 
diet reduced the prevalence of the metabolic syndrome [30, 60]. In addition, 
observational studies showed that a Mediterranean diet was inversely associated with 
the incidence of the metabolic syndrome [28] and the incidence of diabetes mellitus 
type 2 [61] in Spanish adults.
The prevalence of the metabolic syndrome is high in elderly populations, therefore this 
age group may benefit the most from adoption of a Mediterranean diet. However, the 
relationship between a Mediterranean diet and the metabolic syndrome has scarcely 
been studied in elderly populations [62]. We analysed the association between a 
Mediterranean diet and the metabolic syndrome and its characteristics in a study 
among European elderly subjects. As reduced insulin sensitivity is suggested to be 
one the underlying mechanism of the metabolic syndrome [1], we also investigated 
the association between a Mediterranean diet and insulin sensitivity.
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Subjects and Methods
Subjects
We analysed baseline data of the Survey in Europe on Nutrition and the Elderly, a 
Concerted Action (SENECA). In 1988 and 1989, individuals who were born between 
1913 and 1918 and living in small towns across Europe were invited for participation in 
the SENECA study. The towns had a stable population with 10,000-20,000 inhabitants 
and a socioeconomic and population structure representative for its home country [63]. 
Psycho-geriatric patients living in nursing homes, persons who were not fluent in the 
country’s language or not able to independently answer questions were excluded from 
participation. From a subgroup of 1554 SENECA subjects blood samples for serum 
lipid measurements and glucose and insulin measurements were available [64]. These 
subjects lived in 14 towns of 10 countries: Belgium: Hamme; Denmark: Roskilde; France: 
Haguenau and Romans; Hungary: Monor; the Netherlands: Culemborg; Norway: 
Elverum; Switzerland: Yverdon, Burgdorf, and Bellinzona; Greece: Markopoulou and 
Anogia-Archanes; Portugal: Vila Franca de Xira; Spain: Betanzos.
Assessment of dietary intake
The usual dietary intake of the subjects during the month preceding enrolment was 
assessed by trained dieticians using the dietary history method [65]. Food consumption 
data were arranged into food groups following the EUROCODE classification 
system [66]. We used the Mediterranean diet score (MDS) [25] to assess the degree 
of adherence to a Mediterranean diet. This MDS consists of 9 components: ratio of 
monounsaturated to saturated fatty acids (MUFA to SFA); vegetables; legumes; fruits 
plus nuts; cereals; fish; meat plus poultry; dairy products; and alcohol. In our study, 
we had to slightly modify the MDS because some of these food groups were combined 
according to the EUROCODE system. The food group ‘vegetables’ was replaced with 
‘vegetables and potatoes’, the group ‘legumes’ with ‘legumes, nuts and seeds’, and the 
group ‘fruits plus nuts’ with ‘fruits’. For the components MUFA to SFA ratio, vegetables 
and potatoes, legumes, nuts and seeds, fruits, cereals, and fish a value of 1 was assigned 
to subjects whose intake was above the sex specific median, and 0 to others (Table 
3.1). For meat and poultry, and dairy products, a value of 1 was assigned to persons 
whose intake was below the sex specific median, and 0 to others. A value of 1 was also 
assigned to men who consumed between 10 and 50 g alcohol per day and to women 
who consumed between 5 and 25 g alcohol per day. The medians were adjusted for 
energy intake (10.5 MJ for men and 8.4 MJ for women). A MDS above the median 
was used to define good adherence to a Mediterranean diet.
Besides the original MDS we also analysed our data with two modified Mediterranean 
diet scores that were previously used within the SENECA study. In the first modified 
score, optimal intake for dairy products was defined as between the 25th and 75th 
percentile values instead of an intake below the median. In addition, for women the 
upper limit for meat and poultry was defined as 130 g/day instead of the median intake 
[67, 68]. In the second modified score, alcohol was not included in the MDS but the 
statistical models were adjusted for alcohol intake [69].
Chapter 3 
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Metabolic syndrome
The metabolic syndrome is present if at least three of five characteristics are present: 
low HDL-cholesterol concentration (HDL-cholesterol concentration <1.04 mmol/L for 
men and <1.29 mmol/L for women), hypertriglyceridaemia (triglyceride concentration 
≥1.7 mmol), abdominal obesity (waist circumference >102 cm for men and >88 cm 
for women), hyperglycaemia (glucose concentration ≥6.1 mmol/L), and hypertension 
(systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg) 
[6]. Abdominal obesity was assessed by measurement of waist circumference to the 
nearest 0.1 cm midway between the lower rib margin and the iliac crest at the end 
of gentle expiration. Blood samples were taken between 7.30 and 9.30 am while the 
subject was in a fasting state. Serum HDL-cholesterol and triglyceride concentrations 
were measured by the laboratory of the Division of Human Nutrition, Wageningen 
University, Wageningen, the Netherlands [70]. HDL-cholesterol was measured 
after apo-β-lipoprotein precipitation with Dextran sulphate-Mg2+ by the enzymatic 
CHOP-PAP method. After elimination of free glycerol from the samples, triglyceride 
concentration was measured by an enzymatic colorimetric method using Boehringer-
Mannheim reagents. Plasma glucose concentration was measured by the hexokinase 
method using Hitachi 911 auto-analyser. As blood pressure was not measured, we had 
to use a proxy measure for hypertension to enable the estimation of the prevalence of 
the metabolic syndrome. Data on self-reported hypertension that were available from 
a questionnaire were used as proxy measure.
Insulin resistance has been suggested to be the underlying metabolic disturbance of 
the metabolic syndrome [1]. Therefore, we also addressed individual measurements of 
insulin sensitivity such as insulin concentration and insulin resistance. Plasma insulin 
concentration was measured by using enzyme immunoassay (Boehringer-Mannheim, 
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Abbreviation: monounsaturated/saturated fatty acids (MUFA/SFA).
1 After adjustment for energy consumed (10.5 MJ for men and 8.4 MJ for women).
Table 3.1  Sex specific cut-off values (based on medians of the population) and scoring for 
components of the Mediterranean diet score
Components of the Mediterranean diet score Energy adjusted1 sex specific 
cut-off values
Scoring
Male Female
MUFA/SFA ratio 0.98 1.00 > median 1 (else 0)
Vegetables and potatoes, g/day 301 261 > median 1 (else 0)
Legumes, nuts, seeds, g/day 4.0 2.4 > median 1 (else 0)
Fruits, g/day 201 234 > median 1 (else 0)
Cereals, g/day 230 191 > median 1 (else 0)
Fish, g/day 29 28 > median 1 (else 0)
Meat and poultry, g/day 135 102 < median 1 (else 0)
Dairy products, g/day 323 302 < median 1 (else 0)
Alcohol, g/day 10-50 5-25 Within range 1 (else 0)
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Mannheim, Germany) and insulin resistance was estimated using homeostatic model 
assessment insulin resistance (HOMA-IR) from glucose and insulin concentrations 
(http://www.dtu.ox.ac.uk/). 
Other measurements
Information on education level (low or high), smoking status (non-smokers, former 
smokers or current smokers), and presence of chronic disease (including diabetes, 
ischaemic heart disease and stroke) was collected using questionnaires. The Voorrips 
questionnaire, designed to assess physical activity level in elderly people, was used 
to obtain information on habitual physical activity [71]. Subjects were divided into 
three groups according to sex specific tertiles: low, moderate, or high physical activity 
level.
Statistics
After exclusion of subjects because of missing data on outcome variables or potential 
confounders (n=286), data collected from 1258 subjects were used for statistical 
analysis. This subgroup was not substantially different from the source population of the 
SENECA in age and sex distribution and anthropometric measurements. Differences in 
characteristics between subjects with good and poor adherence to a Mediterranean diet 
were tested with Chi-square tests and Students’ t-tests. A Cox-regression model with 
robust error variance was used to estimate the prevalence ratio (PR) of the metabolic 
syndrome for subjects with good adherence to the Mediterranean diet compared with 
subjects with poor adherence [72]. A linear regression model was applied to estimate 
the association between a Mediterranean diet and HDL-cholesterol and triglyceride 
concentrations, waist circumference, glucose and insulin concentrations, and HOMA-
IR. The variables age, sex, physical activity level, type of education, presence of chronic 
disease, smoking status, and study centre were considered to be potentially confounding 
variables. As waist circumference is considered to be an intermediate in the relation 
between a Mediterranean diet and the outcome measures, we did not adjust our analysis 
for waist circumference. Study centre was a confounder and all models were adjusted 
for it. The models with waist circumference as dependent variable were also adjusted 
for sex and physical activity level. The analyses were performed using the statistical 
package SAS, version 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
In this elderly European study population, subjects with good and poor adherence 
to a Mediterranean diet were of similar age and sex (Table 3.2). Subjects with good 
adherence to a Mediterranean diet had higher physical activity scores, lower education 
level and more chronic disease than subjects with poor adherence. The Mediterranean 
diet score was significantly higher in the countries of the Mediterranean region than 
in the non-Mediterranean region (p<0.0001) (Table 3.3).
The prevalence of the metabolic syndrome was lower in subjects with good adherence 
to a Mediterranean diet than in subjects with poor adherence (PR 0.81, 95%CI 0.65; 
1.03), however, this association was not significant at the 5% level (p=0.08). In addition, 
Chapter 3 
22
The SENECA studyChapter 3 
Abbreviations: Mediterranean diet score (MDS). 
1 Median (interquartile range).
Table 3.2  Baseline characteristics of the subjects of the SENECA study
Mediterranean diet score
Poor adherence (MDS ≤4) Good adherence (MDS >4) p-value
N 667 591
Men, N (%) 322 (48) 305 (52) <0.24
Age, years, mean (sd) 73.5 (1.7) 73.4 (1.8) <0.33
Physical activity score1 11.8 (5.9, 19.4) 13.7 (6.6, 23.2) <0.07
Type of education <0.01
Higher education, N (%) 260 (39) 185 (31)
Lower education, N (%) 407 (61) 406 (69)
Chronic disease, N (%) 487 (73) 462 (78) <0.03
Diabetes mellitus, N (%) 51 (8) 58 (10) <0.30
Ischaemic heart disease, N (%) 112 (17) 101 (17) <0.22
Stroke, N (%) 18 (3) 18 (3) <0.30
Smoking status
Non-smoking, N (%) 326 (49) 345 (58) <0.01
Current smoker, N (%) 191 (29) 166 (28) <0.83
Former smoker, N (%) 150 (22) 80 (14) <0.01
Table 3.3  Mean Mediterranean diet score by study centres in Mediterranean and non-
Mediterranean regions
Mediterranean diet score
Country Study centre N Mean (sd)
Non-Mediterranean region 751 3.7 (1.5)
Belgium Hamme 86 3.7 (1.4)
Denmark Roskilde 155 3.1 (1.4)
France Hagenau 54 4.7 (1.5)
Hungary Monor 14 3.8 (1.8)
The Netherlands Culemborg 192 3.6 (1.4)
Norway Elverum 54 2.9 (1.3)
Switzerland Yverdon 151 4.5 (1.4)
Switzerland Burgdorf 45 3.3 (1.5)
Mediterranean region 507 5.3 (1.4)
France Romans 37 4.9 (1.6)
Greece Markopoulou 25 5.9 (1.2)
Greece Anogia Archanes 48 5.7 (1.0)
Portugal Vila Franca de Xira 193 5.3 (1.3)
Spain Betanzos 159 5.2 (1.5)
Switzerland Bellinzona 45 4.6 (1.6)
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subjects with good adherence to a Mediterranean diet had significantly higher HDL-
cholesterol and lower triglyceride concentrations than subjects with poor adherence 
(Table 3.4). Subjects with good adherence to a Mediterranean diet tended to have 
smaller waist circumference than subjects with poor adherence (p=0.11). No significant 
associations were found between a Mediterranean diet and concentrations of glucose 
and insulin or HOMA-IR. 
The use of a modified MDS [67, 68] that included alternative cut-off points for dairy 
products and meat an poultry led to similar conclusions as the original MDS. The use 
of a modified MDS [69] that did not include alcohol in the score resulted in lower 
glucose (-0.19 mmol/L, 95%CI -0.41; 0.04) and insulin concentrations (-5.09 pmol/L; 
95%CI -11.19; 1.02) and HOMA-IR (-0.11; 95%CI -0.23; 0.01) in subjects with good 
adherence to this Mediterranean diet than in subjects with poor adherence, however 
these associations were not statistically significant.
When we investigated the MDS components separately in relation to the characteristics 
of the metabolic syndrome, HDL-cholesterol concentration was significantly higher 
in subjects with a dairy consumption below the median of the population (Table 
3.5). Triglyceride concentration tended to be lower in subjects with meat and poultry 
consumption below the median of the population (p=0.06). Meat and poultry 
consumption below the median was also associated with smaller waist circumference 
(p<0.01). Although no associations were found between a Mediterranean diet with 
glucose, we observed that low meat and poultry consumption was significantly 
associated (p<0.01) with lower glucose concentration.
Table 3.4  Differences in characteristics of the metabolic syndrome and insulin sensitivity 
between subjects with good adherence to a Mediterranean diet (Mediterranean diet score 
(MDS) >4) compared with subjects with poor adherence (MDS ≤4)
Abbreviations: Mediterranean diet score (MDS), homeostatic model assessment insulin resistance (HOMA-IR).
1 Adjusted for study centre.
2 Additionally adjusted for sex and physical activity level.
Characteristics of the metabolic 
syndrome and insulin sensitivity
Mediterranean diet score1 Mean difference1 95%CI
Poor adherence 
(MDS ≤4)
Good adherence 
(MDS >4)
Good-poor
Mean (se) Mean (se)
N 667 591
HDL-cholesterol, mmol/L 1.27 (0.01) 1.32 (0.02) -0.05 -0.00; 0.10
Triglyceride, mmol/L 1.51 (0.04) 1.39 (0.04) -0.12 -0.24; 0.00
Waist circumference2, cm 93.7 (0.4) 92.6 (0.5) -1.1 -2.4; 0.3
Glucose, mmol/L 6.06 (0.07) 6.03 (0.08) -0.03 -0.25; 0.19
Insulin, pmol/L 74.15 (1.93) 71.75 (2.07) -2.40 -8.33; 3.53
HOMA-IR 1.44 (0.04) 1.39 (0.04) -0.05 -0.17; 0.06
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Discussion
Good adherence to a Mediterranean diet was associated with higher HDL-cholesterol 
and lower triglyceride concentrations but not with measures of insulin sensitivity in 
European elderly subjects. Although not statistically significant, elderly subjects with 
good adherence to a Mediterranean diet had a lower prevalence of the metabolic 
syndrome and tended to have smaller waist circumference than elderly subjects with 
poor adherence.
To our knowledge, the relation between a Mediterranean diet and HDL-cholesterol 
and triglyceride concentrations has only scarcely been studied in apparently healthy 
elderly populations [62]. Two Spanish cross-sectional studies in an on average younger 
(6-75 years or 18-75 years) study populations did not show an association between a 
Mediterranean diet and triglyceride concentration [29, 73], however, an association 
with higher HDL-cholesterol concentration was found in one of the studies [73]. Several 
intervention studies showed that a Mediterranean diet increased HDL-cholesterol 
and decreased triglyceride concentrations in subjects at high cardiovascular risk [30, 
31]. In the context of the results of those intervention studies, our results support the 
hypothesis that a Mediterranean diet may not only have a beneficial effect on HDL-
cholesterol and triglyceride concentrations in high-risk populations but also in elderly 
subjects.
Out of the Mediterranean components, dairy consumption below the median of 
the study population was significantly associated with higher HDL-cholesterol 
concentration but not with lower triglyceride concentration. In contrast, observational 
studies found that a high calcium consumption was associated with higher HDL-
cholesterol concentration in women between 30 and 65 years [74] and in middle-aged 
and elderly women [75]. Furthermore, no association between dairy consumption and 
HDL-cholesterol was found in a Dutch elderly population [76]. These inconsistent 
findings may be caused by the lack of distinction between more healthy dairy products 
such as low-fat dairy products and less healthy dairy products such as high-fat dairy 
products. Because of the classification of foods according to the EUROCODE system we 
could not disentangle the effects of the types of diary products. It is therefore possible 
that in our study, subjects with a low dairy consumption were consuming more low-fat 
dairy products than the subjects with a high dairy consumption.
Our results showed that low meat and poultry consumption is associated with lower 
triglyceride concentration and they also suggest that low meat and poultry consumption 
is associated with higher HDL-cholesterol concentration. In a cross-sectional study 
in young adults, no association between meat consumption and HDL-cholesterol 
concentration was observed [77]. In another cross-sectional study in young adults, 
lower triglyceride concentration but similar HDL-cholesterol concentration was 
observed in subjects who consumed red meat and poultry less than once a week 
compared with subjects who consumed meat more frequently [78]. The latter study 
suggests the type of meat may also be important in studying the association between 
meat consumption and HDL-cholesterol and triglycerides. As we used the EUROCODE 
system as indicated earlier, we could not distinguish between types of meat.
Besides low consumption of dairy products or meat and poultry, other components 
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of the MDS such as high MUFA/SFA ratio and high intake of legumes, nuts and seeds 
tended to be associated with higher HDL-cholesterol concentrations. Although these 
associations were not statistically significant, they are in line with the finding of other 
studies that found favourable effects of these components on serum lipid profiles [79-
81]. These findings suggest that these components are important contributors to the 
Mediterranean diet.
Our results also suggest that elderly subjects with good adherence to a Mediterranean 
diet have smaller waist circumference than subjects with poor adherence. Our results 
agree with the findings of two intervention studies that showed that consuming a 
Mediterranean diet substantially decreased waist circumference [30, 82]. Out of all 
Mediterranean components, low meat and poultry consumption was significantly 
associated with smaller waist circumference. These results are in line with findings 
from a cohort study in British adults [83] and a study combining data of the US 
Framingham Heart Study and the SENECA study [84].
Our study did not show an association between a Mediterranean diet with glucose 
and insulin concentrations or HOMA-IR, but elderly subjects with meat and poultry 
consumption below the median had significantly lower glucose concentrations. Our 
results are in line with the results of the Spanish cross-sectional study in younger 
subjects [29] that also found no association between a Mediterranean diet with insulin 
concentration and HOMA-IR. Intervention studies in subjects at high cardiovascular 
risk showed that a Mediterranean diet improved insulin sensitivity [30, 31]. However, 
an intervention study in a healthy study population did not show an effect of a 
Mediterranean diet on insulin sensitivity [32]. Results of these intervention studies, in 
combination with results of cross-sectional studies so far, suggest that a Mediterranean 
diet may be more effective to improve insulin sensitivity in persons with a high-risk 
profile than in healthy persons. However, the results of the Greek Attica study seem 
to contradict this hypothesis. In the Attica study adherence to a Mediterranean diet 
was associated with insulin and HOMA-IR in healthier subjects with a normal glucose 
tolerance but not in subjects with an impaired glucose tolerance or diabetes mellitus 
and therefore at higher risk for cardiovascular diseases [33].
Although no associations were found with the original MDS, insulin concentrations 
and HOMA-IR tended to be lower in subjects who adhered to the alternative MDS, 
which did not include alcohol consumption as component [69]. These associations 
were adjusted for alcohol intake and were not significant. As our study is the first to 
report the relation between a Mediterranean diet and insulin sensitivity in an elderly 
population and the results of studies in other age groups are inconsistent, we cannot 
exclude the possibility that a Mediterranean diet is related to insulin sensitivity in 
elderly populations.
An advantage of the SENECA study was the participation of study centres in both 
Mediterranean and non-Mediterranean countries that resulted in a large diversity 
in adherence to a Mediterranean diet. However, in multi-centre studies, nutritional 
and lifestyle factors are influenced by cultural differences between research centres. 
Consequently, we carried out our analysis with study centre in our model. Adjustment 
for study centre is likely to result in an overcorrection of the true association between 
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the MDS and characteristics of the metabolic syndrome, but with disregard of this 
confounder no adjustments are made for non-diet related differences across study 
centres.
A possible limitation of the study was that our data could have been influenced by 
selective participation. Healthy elderly were most willing to participate in the SENECA 
study [65] and this could have diluted the association between a Mediterranean 
diet and the characteristics of the metabolic syndrome. In addition, the data of the 
SENECA study were collected in 1988 and 1989, therefore the study population may 
not be representative for the present European elderly. However, we do not expect 
the association between a Mediterranean diet and the metabolic syndrome to be 
different nowadays. Other limitations are related to the assessment of the MDS and 
the metabolic syndrome. We had to use a modified version of the MDS in which 
nuts were considered together with legumes in stead of with fruits and potatoes were 
considered together with vegetables instead of with cereals. These modifications of 
the MDS limit the comparability of our study with the studies of others. For the blood 
pressure characteristic of the metabolic syndrome we had to rely on self-reported 
hypertension instead of measured blood pressure.
Our results showed that elderly subjects with good adherence to a Mediterranean diet 
had higher HDL-cholesterol and lower triglyceride concentrations and tended to have 
smaller waist circumference than elderly subjects with poor adherence. It is therefore 
likely that good adherence to this diet is also associated with the metabolic syndrome 
in elderly populations.
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Abstract
Background and aims: Intervention studies have suggested that in subjects with high-
risk of cardiovascular disease a Mediterranean diet is more effective to improve insulin 
sensitivity than in healthy subjects. However, one Greek observational study suggests 
the opposite. We investigated the cross-sectional association between a Mediterranean 
diet and markers of glucose metabolism in Dutch healthy subjects with normal glucose 
tolerance and in high-risk subjects with impaired glucose regulation or with diabetes 
mellitus type 2.
Methods and results: A Mediterranean diet was assessed by the Mediterranean diet score 
(MDS range 0 through 9). In subjects with normal glucose tolerance, a Mediterranean 
diet was not associated with insulin and glucose concentrations, homeostatic model 
assessment, or HbA1c levels. In subjects with diabetes mellitus type 2, glucose 
concentration was higher (0.6 mmol/L, 95%CI 0.0; 1.2) and HbA1c level tended to be 
higher (0.3%, 95%CI -0.2; 0.7) in subjects with good adherence to a Mediterranean diet 
(MDS >4), than in subjects with poor adherence (MDS ≤4). No associations were found 
in subjects with impaired glucose regulation. Analyses were adjusted for age, prescribed 
dietary treatment, physical activity level, current smoking, family history of diabetes 
mellitus type 2, and use of antihypertensive or cholesterol lowering medication.
Conclusion: In our data we did not find support for a differential beneficial effect of a 
Mediterranean diet on insulin sensitivity in healthy subjects versus high-risk subjects.
Introduction
Reduced insulin sensitivity is a risk factor for diabetes mellitus type 2 and cardiovascular 
disease [85]. Interest has focused on the potential of a Mediterranean diet as protective 
against reduced insulin sensitivity [36, 86]. This Mediterranean diet refers to a dietary 
pattern as consumed in countries of the Mediterranean region during the early 1960s, 
and is characterised by abundant use of plant foods (fruits, vegetables, cereals, legumes, 
nuts, and seeds) and olive oil, moderate intake of fish and wine, and low to moderate 
consumption of dairy products and meat and poultry [24-26]. A Mediterranean diet 
improved insulin sensitivity in intervention studies among subjects with a high risk 
of cardiovascular disease [30, 31], but not among subjects without a high risk [32]. 
These results suggest that a Mediterranean diet may be more effective to improve 
insulin sensitivity in high-risk subjects than in healthy subjects. However, one Greek 
observational study showed an association between a Mediterranean diet and insulin 
sensitivity in healthy subjects with normal glucose tolerance but not in high-risk 
subjects with impaired glucose regulation or with diabetes mellitus type 2 [33]. These 
findings contradict the results of the intervention studies, therefore they need to be 
confirmed. The Cohort study on Diabetes and Atherosclerosis Maastricht (CoDAM) 
in the Netherlands included healthy subjects with normal glucose tolerance and a 
high number of high-risk subjects with impaired glucose regulation or with diabetes 
mellitus type 2. We investigated the association between a Mediterranean diet and 
markers of glucose metabolism in healthy subjects and in high-risk subjects of the 
CoDAM study. As reduced insulin sensitivity is suggested to be one of the underlying 
mechanisms of the metabolic syndrome [1], we also investigated the association 
between a Mediterranean diet and the metabolic syndrome.
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Methods
Study population
We used data of the CoDAM study (1999-2000). The subjects of the CoDAM study 
were recruited from a study that monitored health and disease in the general Dutch 
population [50, 51]. Inclusion criteria for participation in the CoDAM study were 
Caucasian ethnicity, age between 40 and 70 years, and at least one of the criteria: 
BMI >25 kg/m2, positive family history of diabetes mellitus type 2, history of 
gestational diabetes, postprandial blood glucose > 6.0 mmol/L, glucosuria, or use 
of antihypertensive medication or medication known to affect glucose metabolism. 
Each subject who agreed to participate and fulfilled the inclusion criteria underwent 
two glucose tolerance tests except for 66 subjects who were already diagnosed with 
diabetes mellitus. The first test assessed glucose tolerance status using capillary blood 
samples and the second test using venous blood plasma. Subjects were classified into 
three groups of glucose tolerance status according to criteria of the World Health 
Organization [4]: normal glucose tolerance, impaired glucose regulation or diabetes 
mellitus type 2. In total, data from 574 subjects were available for analyses: 301 subjects 
with normal glucose tolerance, 127 subjects with impaired glucose regulation, 80 
subjects with newly diagnosed diabetes mellitus type 2 and 66 subjects with ‘known’ 
diabetes mellitus type 2. Each subject gave written informed consent and the medical 
ethics committee of Maastricht University approved the study protocol.
Dietary assessment
A self-administered semi-quantitative food-frequency questionnaire was used to 
estimate the average consumption of 178 food items during the past year. For 21 food 
items, portion size was assessed using colour photographs of 2-4 differentially sized 
portions. For other food items, portion size was assessed by household measures 
(slices, glasses, etc.). The questionnaire was developed to assess habitual dietary 
intake in the Dutch cohort of the European Prospective Investigation into Cancer and 
nutrition and is a good method to rank people according to energy, macronutrients 
and food groups intakes [87, 88]. Intakes of energy and nutrients were calculated using 
the Dutch food-composition table (NEVO 2001). We excluded data of subjects who 
had a large inconsistency between the answers on questions about the frequency of 
a hot meal and frequency of meat and vegetable consumption (n=49). Adherence to 
a Mediterranean diet was assessed by the Mediterranean Diet Score (MDS) [25]. In 
this score, a Mediterranean diet is characterised by 9 components: (1) High ratio of 
monounsaturated to saturated fatty acids (MUFA to SFA), high intakes of (2) cereals 
(including bread and potatoes), (3) legumes, (4) fruits and nuts, (5) vegetables, and 
(6) fish, low intakes of (7) dairy products, (8) meat and poultry and (9) alcohol 
consumption between 10 through 50 g/day for men and between 5 through 25 g/day 
for women. For each protective component (1 through 6), a value of 1 was assigned 
to each subject whose intake was more than the energy-adjusted median. For each 
non-protective component [7, 8], a value of 1 was assigned to each subject whose 
intake was less than the energy-adjusted median. For alcohol intake [9], a value of 1 
was also assigned to each subject whose intake was within the range (Table 4.1). The 
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intakes were adjusted for energy intake (10.5 MJ for men and 8.4 MJ for women), 
therefore the medians are independent of variations in energy intake. Good adherence 
to a Mediterranean diet was defined by MDS above its median (MDS >4) and poor 
adherence was defined by MDS lower or equal to its median (MDS ≤4).
Laboratory measurements
Blood samples were taken from the antecubital vein while the subject was in a fasting 
state. Plasma glucose concentration was measured by the hexokinase method (HK-
G6PD method, ABX Diagnosis, Montepellier, France) at the Department of Clinical 
Chemistry of the VU University Medical Centre, Amsterdam, the Netherlands. HbA1c 
level was measured by using ion-exchange high performance liquid chromatography 
at the Department of Clinical Chemistry of the University Hospital Maastricht, 
Maastricht, the Netherlands. Plasma insulin concentration was measured by a two-sided 
immunoradiometric test using paired monoclonal antibodies (Medgenix Diagnostics, 
Fleurus, Belgium) at the Endocrinological Laboratory of the VU University Medical 
Centre. Homeostasis model assessment (HOMA) was used to assess insulin resistance 
(HOMA-IR) and β-cell function (HOMA-B) from glucose and insulin concentrations 
(http://www.dtu.ox.ac.uk/). HDL-cholesterol and triglyceride concentrations were 
determined using enzymatic methods (Roche Mannheim, Germany) at the Department 
of Clinical Chemistry of VU University Medical Centre.
Other measurements
Height and body weight were measured with subjects wearing light indoor clothing 
and no shoes. Waist circumference was measured midway between the lateral lower 
rib margin and the spina iliaca anterior superior. Blood pressure was measured twice 
on the right arm with the subject in supine position after 5 minutes of rest using a 
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Table 4.1  Sex-specific cut-off values (based on medians of the population) and scoring for 
components of the Mediterranean diet score
Abbreviation: monounsaturated/saturated fatty acids (MUFA/SFA).
1 After adjustment for energy consumed (10.5 MJ for men and 8.4 MJ for women).
Components of the Mediterranean 
diet score
Energy adjusted1 
sex specific cut-off values
Scoring
Male Female
MUFA/SFA 0.84 0.81 > median 1 (else 0)
Cereals, g/day 419 314 > median 1 (else 0)
Legumes, g/day 6 4 > median 1 (else 0)
Fruits and nuts, g/day 195 226 > median 1 (else 0)
Vegetables, g/day 138 162 > median 1 (else 0)
Fish, g/day 10 11 > median 1 (else 0)
Dairy products, g/day 248 284 < median 1 (else 0)
Meat and poultry, g/day 149 99 < median 1 (else 0)
Alcohol, g/day 10-50 5-25 Within range 1 (else 0)
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precision aneroid sphygmomanometer (Speidel & Kelly Maxi Stabil 3, Jungingen, 
Germany). Systolic blood pressure (SBP) was defined according to Korotkoff sound 
I and diastolic blood pressure (DBP) according to Korotkoff sound V. The mean of 
the two measurements was used in the analyses. The Short Questionnaire to Assess 
Health-enhancing physical activity (SQUASH) was used to rank subjects according to 
their level of physical activity [89]. Each subject filled in a questionnaire about medical 
status, medicine use, and risk factors of cardiovascular disease such as smoking and 
family history of diabetes mellitus type 2.
Metabolic syndrome assessment
The metabolic syndrome was diagnosed using the National Cholesterol Education 
Program (NCEP) criteria (2001), which were modified in 2005 [10]. According to 
these criteria, a subject is diagnosed with the metabolic syndrome when at least three 
of five characteristics are present: abdominal obesity (waist circumference >102 cm for 
men and >88 cm for women), hypertriglyceridaemia (triglyceride concentration ≥1.7 
mmol), low HDL-cholesterol concentration (HDL-cholesterol concentration <1.04 
mmol/L for men and <1.29 mmol/L for women), hypertension (SBP ≥130 mmHg and/
or DBP ≥85 mmHg or use of anti-hypertensive medication), hyperglycaemia (glucose 
concentration ≥5.6 mmol/L or drug treatment for elevated glucose levels). Fibrates and 
nicotinic acid are the most commonly used drugs to treat hypertriglyceridaemia and 
low HDL-cholesterol concentration. Subjects taking one of these drugs were presumed 
to have hypertriglyceridaemia and low HDL-cholesterol concentration [10].
Statistics
After the exclusion of subjects with known diabetes mellitus (n=66) or unreliable data 
on their food consumption or with missing data on markers of glucose metabolism, 
data of 450 subjects were used for statistical analyses. A linear-regression model was 
used to assess the association between a Mediterranean diet and markers of glucose 
metabolism. A Cox-regression model with robust error variance was used to estimate 
the prevalence ratio (PR) of the metabolic syndrome for subjects with good adherence 
to the Mediterranean diet compared with subjects with poor adherence [72]. We 
included an interaction term in the models to test whether the association between a 
Mediterranean diet and the outcome measures differed among subjects with normal 
glucose tolerance, impaired glucose regulation, or diabetes mellitus type 2. All models 
were adjusted for potential confounding variables: age, prescribed dietary treatment, 
physical activity level, current smoking, family history of diabetes mellitus type 2, and 
use of antihypertensive or lipid lowering medication (statins, fibrates or nicotinic acid). 
The Cox-regression models with metabolic syndrome as dependent variable were not 
adjusted for use of lipid-lowering or antihypertensive medication because medication 
use was included in the definition of the metabolic syndrome. Similarly, the Cox-
regression models with hypertriglyceridaemia or low HDL-cholesterol as dependent 
variable were not adjusted for use of lipid lowering medication and the model with 
hypertension as dependent variable was not adjusted for use of antihypertensive 
medication. The statistical SAS package, version 9.1 (SAS Institute Inc., Cary, NC, 
USA), was used to perform the analyses.
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Results
Out of 450 subjects, 275 subjects (61%) had normal glucose tolerance, 111 subjects 
(25%) had impaired glucose regulation, and 64 subjects (14%) had diabetes mellitus 
type 2. There were no differences among subjects with normal glucose tolerance, 
impaired glucose regulation, or diabetes mellitus type 2 in age, gender, current 
smoking, adherence to the Dutch physical activity guidelines or good adherence to 
a Mediterranean diet (Table 4.2). The metabolic syndrome and the characteristics of 
the metabolic syndrome were most prevalent in subjects with diabetes mellitus type 2. 
The percentage of subjects that followed a prescribed dietary treatment was higher in 
subjects with diabetes mellitus type 2 or impaired glucose regulation compared with 
subjects with normal glucose tolerance. 
Subjects with good adherence to a Mediterranean diet had higher MUFA/SFA ratio 
and higher intakes of cereals, legumes, fruits and nuts, and fish than subjects with poor 
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Table 4.2  Characteristics (mean (sd)) according to glucose tolerance status
Abbreviations: homeostasis model assessment insulin resistance (HOMA-IR), homeostasis model assessment 
β-cell function (HOMA-B), glycated haemoglobin (HbA1c), diabetes mellitus (DM).
1 Median (interquartile range).
2 Normal glucose tolerance, N=266; impaired glucose tolerance, N=107; diabetes mellitus type 2, N=63
Metabolic syndrome was defined according to the NCEP criteria [10].
Characteristics Glucose tolerance status
Normal glucose 
tolerance
Impaired glucose 
regulation
Diabetes mellitus 
type 2
N=275 N=111 N=64
Men, N (%) 163 (59) 66 (59) 45 (70)
Age, years 58.5 (7.3) 59.6 (6.7) 59.6 (6.5)
Body mass index, kg/m2 27.7 (4.0) 28.8 (4.4) 29.1 (4.0)
Insulin1, pmol/L 52.0 (42.0, 70.0) 66.0 (45.0, 101.0) 78.0 (52.0, 115.5)
HOMA-IR1 1.0 (0.8, 1.3) 1.3 (0.9, 1.9) 1.5 (1.0, 2.3)
HOMA-B 91.8 (25.5) 86.8 (33.8) 67.7 (32.4)
Glucose, mmol/L 5.3 (0.4) 5.9 (0.5) 7.2 (1.1)
HbA1c2, % 5.6 (0.4) 5.8 (0.4) 6.4 (0.7)
Good adherence to a Mediterranean diet, N (%) 116 (42) 54 (49) 31 (48)
Physical activity level (>30 min/day at moderate 
intensity at least 5 days/week), N (%)
179 (65) 64 (58) 40 (63)
Family history of DM, N (%) 99 (36) 56 (50) 31 (48)
Current smoking, N (%) 59 (21) 20 (18) 12 (19)
Following prescribed dietary treatment, N (%) 21 (8) 22 (20) 15 (23)
Metabolic syndrome, N (%) 90 (33) 75 (68) 54 (84)
Hypertriglyceridaemia, N (%) 70 (25) 52 (47) 38 (59)
Low HDL-cholesterol, N (%) 104 (38) 52 (47) 36 (56)
Abdominal obesity, N (%) 130 (47) 66 (59) 43 (67)
Hyperglycaemia, N (%) 55 (20) 82 (74) 60 (94)
Hypertension, N (%) 190 (69) 97 (87) 62 (97)
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adherence to Mediterranean diet (Table 4.3). Mean intakes of dairy products, meat 
and poultry and alcohol were not significantly different between subjects with good 
adherence to a Mediterranean diet and subjects with poor adherence. 
In subjects with normal glucose tolerance, a Mediterranean diet was not associated 
with insulin or glucose concentration, HbA1c levels, or HOMA scores (Table 4.4). In 
subjects with impaired glucose regulation or diabetes mellitus type 2, a Mediterranean 
diet was not associated with insulin concentration or HOMA scores. However, in 
subjects with diabetes mellitus type 2 glucose concentration was higher (0.6 mmol/L, 
95%CI 0.0; 1.2) and HbA1c level tended to be higher (0.3%, 95%CI -0.2; 0.7) in subjects 
with good adherence to a Mediterranean diet, than in subjects with poor adherence. 
No associations between a Mediterranean diet and glucose or HbA1c were found in 
subjects with impaired glucose regulation.
In the total population, a Mediterranean diet was not associated with the metabolic 
syndrome (PR 1.0, 95%CI 0.8; 1.2). In addition, a Mediterranean diet was not associated 
with hypertriglyceridaemia (PR 1.1, 95%CI 0.9; 1.5), low HDL-cholesterol (PR 1.2, 
95%CI 0.9; 1.4), hyperglycaemia (PR 1.1, 95%CI 0.9; 1.2) or hypertension (PR 0.9, 
95%CI 0.9; 1.1). These associations were not different among subjects with normal 
glucose tolerance, impaired glucose regulation or diabetes mellitus type 2. Subjects 
with normal glucose tolerance with good adherence to a Mediterranean diet had 
less abdominal obesity than subjects with poor adherence (PR 0.7, 95%CI 0.6; 1.0). 
However, subjects with diabetes mellitus type 2 with good adherence to a Mediterranean 
diet tended to have more abdominal obesity than subjects with poor adherence (PR 
1.3, 95%CI 0.9; 1.8). No association between a Mediterranean diet and abdominal 
obesity was found in subjects with impaired glucose regulation.
Table 4.3  Mean energy adjusted intakes1 (sd) of Mediterranean components of subjects 
with poor and good adherence to a Mediterranean diet
Abbreviations: Mediterranean diet score (MDS), monounsaturated/saturated fatty acids (MUFA/SFA).
1 After adjustment for energy consumed (10.5 MJ for men and 8.4 MJ for women).
Components of the 
Mediterranean diet score
Mediterranean diet score
Poor adherence (MDS ≤4) Good adherence (MDS >4) p-value
Mean (sd) Mean (sd)
N 249 201
MUFA/SFA 0.82 (0.13) 0.88 (0.12) <0.001
Cereals, g/day 361 (109) 416 (121) <0.001
Legumes, g/day 6 (10) 11 (10) <0.001
Fruits and nuts, g/day 202 (129) 264 (145) <0.001
Vegetables, g/day 136 (58) 182 (69) <0.001
Fish, g/day 10 (12) 18 (20) <0.001
Dairy products, g/day 327 (230) 294 (242) <0.14
Meat and poultry, g/day 135 (57) 128 (61) <0.20
Alcohol, g/day 14 (19) 17 (17) <0.07
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Discussion
No beneficial associations between a Mediterranean diet and markers of glucose 
metabolism were found. Therefore, the present paper does not provide support for 
a differential beneficial effect of a Mediterranean diet in healthy versus high-risk 
subjects.
By recruiting high-risk subjects from a monitoring study, we managed to include a 
large number of high-risk subjects in our study. Our study had a cross-sectional design, 
therefore we cannot preclude the possibility that predominantly subjects with impaired 
glucose regulation or diabetes mellitus type 2 might have adopted a healthier diet 
prior to our study. Although subjects were unaware of their glucose tolerance status 
when they reported their dietary pattern, other conditions closely related to impaired 
glucose regulation such as abdominal obesity, hypertension or dyslipidaemia may have 
influenced dietary patterns. This influence is suggested by the higher percentage of 
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Table 4.4  Differences in markers of glucose metabolism between subjects with good 
adherence to a Mediterranean diet and subjects with poor adherence among subjects with 
normal glucose tolerance, impaired glucose tolerance or diabetes mellitus type 2
Abreviations: impaired glucose regulation (IGR), diabetes mellitus type 2 (DM2), homeostasis model 
assessment insulin resistance (HOMA-IR), homeostasis model assessment β-cell function (HOMA-B), glycated 
haemoglobin (HbA1c).
Full models are adjusted for age, prescribed dietary treatment, physical activity level, current smoking, family 
history of diabetes mellitus, use of antihypertensive or lipid lowering medication.
1 Normal glucose tolerance, N=266; impaired glucose tolerance, N=107; diabetes mellitus type 2, N=63.
Markers of glucose 
metabolism
Glucose tolerance status
Normal glucose 
tolerance
N=275
Impaired glucose 
regulation
N=111
Diabetes mellitus 
type 2
N=64
Interaction
IGR/DM2
estimate 95%CI estimate 95%CI estimate 95%CI p-values
Plasma insulin, pmol/L
Crude model 1.6 -5.2; 8.4 7.9 -9.3; 25.2 0.6 -23.7; 22.41 0.44/ 0.82
Full model 0.5 -6.4; 7.4 8.8 -9.5; 27.0 -1.5 -26.0; 23.0 0.37/ 0.86
HOMA-IR
Crude model 0.0 -0.1; 0.2 0.2 -0.2; 0.5 0.0 -0.4; 0.5 0.44/ 0.94
Full model 0.0 -0.1; 0.1 0.2 -0.2; 0.5 0.0 -0.5; 0.5 0.37/ 0.98
HOMA-B
Crude model 0.4 -6.0; 6.8 1.5 -11.2; 14.3 -9.5 -25.7; 6.7 0.87/ 0.23
Full model 0.9 -5.7; 7.5 4.4 -8.8; 17.6 -11.5 -29.1; 6.1 0.75/ 0.25
Plasma glucose, mmol/L
Crude model 0.0 -0.1; 0.1 0.1 -0.1; 0.3 0.5 0.0; 1.0 0.62/ 0.002
Full model 0.0 -0.1; 0.1 0.1 -0.1; 0.3 0.6 0.0; 1.2 0.74/ 0.002
HbA1c1, %
Crude model 0.0 -0.1; 0.1 0.0 -0.2; 0.1 0.2 -0.2; 0.6 0.61/ 0.19
Full model 0.0 -0.1; 0.1 -0.1 -0.2; 0.1 0.3 -0.2; 0.7 0.77/ 0.11
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subjects that followed a prescribed diet in high-risk subjects (21%) compared with 
healthy subjects (8%). 
Our results, which suggest an adverse effect of a Mediterranean diet in subjects with 
diabetes mellitus type 2, may be due to the high number of subjects with abdominal 
obesity in this group (67%) compared with subjects with impaired glucose regulation 
(59%) or healthy subjects (47%). It has been suggested that subjects with obesity 
underreport energy intake [90] and report more healthy dietary habits than those 
they actually have consumed. Despite the validated methodology for assessing dietary 
intakes, the high number of subjects with abdominal obesity along with the low 
number of subjects with diabetes mellitus type 2 might explain the unexpected positive 
association between a Mediterranean diet and glucose concentrations.
Our study does not confirm the findings of the study by Panagiotakos et al. [33], 
the only (cross-sectional) study that also compared healthy subjects with high-risk 
subjects, and that did find an association between a Mediterranean diet and markers 
of glucose metabolism in healthy subjects. In the study by Panagiotakos et al., good 
adherence to a Mediterranean diet was assessed by a Mediterranean diet score (range 
0-55). In our study, we applied the Mediterranean diet score that was developed by 
Trichopoulou et al. [25]. This Mediterranean diet score has been associated with 
mortality in Northern Europe [91], therefore, we a priori assumed sufficient between-
subject variation in intake of Mediterranean food components in our study. Such 
variation is needed for detecting an association between a Mediterranean diet and 
markers of glucose metabolism. In actual comparisons of our intakes with the intakes 
in the Northern European study we found similar variation in intake of Mediterranean 
food components.
Although the variability in intakes of Mediterranean components seemed sufficient, 
the diet of subjects with good adherence to a Mediterranean diet does not necessarily 
resemble the diet that was consumed in countries of the Mediterranean region during 
the early 1960s. In 1960, men living in Crete (Greece) who participated in the Seven 
Countries Study had on average higher intakes of legumes (26 g/day), fruits (410 g/
day), vegetables (169 g/day), and fish (16 g/day) and lower intakes of dairy products 
(219 g/day) and meat and poultry (44 g/day) than men in our study [92]. In addition, 
a MUFA/SFA ratio of at least above 1 is expected in a traditional Mediterranean 
diet that contains abundant olive oil, whereas in our study the median MUFA/SFA 
ratio was around 0.8. Therefore, the contrast between good and poor adherence to a 
Mediterranean diet in our study might be smaller compared with studies performed in 
the Mediterranean region. The smaller contrast in our study might explain why we were 
not able to confirm the results of the study by Panagiotakos et al. [33]. Contrary to the 
findings of intervention studies, our findings do not underpin the observed beneficial 
effects of providing a Mediterranean diet to high-risk subjects [30, 31]. This might be 
due to stronger dietary contrasts that were introduced in intervention studies.
The association between a Mediterranean diet and the metabolic syndrome has been 
studied before in three observational studies from the South of Europe. Two of these 
studies found that a Mediterranean diet was associated with a lower prevalence of the 
metabolic syndrome in Greece [27] or a lower incidence of the metabolic syndrome 
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in Spain [28] and one Spanish study found no association [29], which was in line with 
the present study. 
In our study that included both healthy and high-risk subjects from a Northern 
European population, we did not find support for the hypothesis that a Mediterranean 
diet would be more effective to improve markers of glucose metabolism in high-risk 
subjects than in healthy subjects.
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Abstract
Background and aims: Diets high in monounsaturated fatty acids (MUFA) such as a 
Mediterranean diet may reduce the risk of cardiovascular diseases by improving insulin 
sensitivity and serum lipids. Besides being high in MUFA, a Mediterranean diet also 
contains abundant plant foods, moderate wine and fish, and low amounts of meat and 
dairy products, which may also play a role. We compared the effects of a high MUFA-diet 
with a diet high in saturated fatty acids (SFA) and the additional effect of a Mediterranean 
diet on insulin sensitivity and serum lipids.
Methods and results: A randomized parallel controlled-feeding trial was performed in 
60 non-diabetics (40-65 years) with mild abdominal obesity. After a two week run-in diet 
high in SFA (19% of total energy intake (energy-%)), subjects were allocated to a high 
MUFA-diet (20 energy-%), a Mediterranean diet (MUFA 21 energy-%), or the high SFA-
diet, for eight weeks. The high MUFA and the Mediterranean diet did not affect fasting 
insulin concentrations. The high MUFA-diet reduced total cholesterol (-0.41 mmol/L, 
95%CI -0.74; -0.09) and LDL-cholesterol (-0.38 mmol/L, 95%CI -0.65; -0.11) compared 
with the high SFA-diet, but not triglyceride concentrations. The Mediterranean diet 
increased HDL-cholesterol concentrations (+0.09 mmol/L, 95%CI 0.0; 0.18) and reduced 
the ratio of total cholesterol/HDL-cholesterol (-0.39, 95%CI -0.62; -0.16) compared with 
the high MUFA-diet.
Conclusion: Replacing a high SFA-diet with a high MUFA or a Mediterranean diet did 
not affect insulin sensitivity, but improved serum lipids. The Mediterranean diet was most 
effective, it reduced total and LDL-cholesterol, and also increased HDL-cholesterol and 
reduced total cholesterol/HDL-cholesterol ratio.
Introduction
Dietary fatty acids affect metabolic risk profiles for diabetes mellitus and cardiovascular 
disease [34, 93]. Replacing saturated fatty acids (SFA) with monounsaturated fatty acids 
(MUFA) reduces total cholesterol, LDL-cholesterol, and triglyceride concentrations 
[39]. Replacing SFA with MUFA may also improve insulin sensitivity as observational 
studies showed that diets high in SFA are associated with reduced insulin sensitivity [34, 
94], and intervention studies showed that insulin sensitivity increased after replacing 
SFA with MUFA [40, 41].
Olive oil is rich in MUFA, and is the main source of fat in a Mediterranean diet 
[24]. A Mediterranean diet is characterised by abundant use of plant foods (fruits, 
vegetables, cereals, legumes, nuts, and seeds), moderate intake of fish and wine, and 
low to moderate consumption of dairy products, meat and poultry [24-26]. Some of 
these components, such as nuts, fish, dietary fibre, and alcohol may also favourably 
affect serum lipids or insulin sensitivity [35-38, 95]. Thus, the cumulative effect of the 
multiple Mediterranean components on serum lipids and insulin sensitivity may be 
larger than the effect of a high MUFA-diet alone.
Intervention studies showed that a Mediterranean diet reduced total cholesterol and 
insulin concentrations more than a diet lower in MUFA [30, 31]. However, they were 
unable to determine whether the effects of the Mediterranean diet were due to the 
high MUFA content of the diet or to the cumulative effect of the Mediterranean diet 
components. We studied whether replacing a high SFA-diet with a high MUFA-diet 
improved serum lipids and insulin sensitivity. In addition, we examined whether a 
Mediterranean diet with a high MUFA content and other Mediterranean components 
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improved serum lipids and insulin sensitivity more than a high MUFA-diet. We 
conducted a parallel controlled-feeding trial, in which we controlled energy intake 
and macronutrient composition of the intervention diets.
Methods
Study population
Subjects were recruited from Wageningen and surroundings. Men and women who 
did not use antihypertensive or cholesterol-lowering medication, and without diabetes 
mellitus were invited for a screening visit. We included subjects aged 40-65 years with 
a BMI ≥25 kg/m2 or a waist circumference ≥94cm for men and ≥80 cm for women 
to have a study population with a higher chance of reduced insulin sensitivity. We 
excluded subjects with fasting total cholesterol ≥8 mmol/L, subjects who consumed 
more than 4 glasses of alcohol/day, subjects who participated in other dietary or 
drugs trials <4 weeks before the start of the study, and pregnant or lactating women. 
We performed an oral glucose-tolerance test to exclude non-treated diabetics [4]. We 
used questionnaires to collect information about general characteristics and medical 
status. All 60 eligible subjects were asked to undergo a hyperinsulinemic-euglycemic 
clamp to measure insulin sensitivity and 30 subjects agreed to participate. All subjects 
signed informed consent. 
Study design
The study was conducted from January to April 2007 at Wageningen University. The 
medical ethical committee of Wageningen University approved the study. All 60 subjects 
received a Western-style diet high in SFA (19% of total energy intake (energy-%)) for a 
two weeks run-in period to standardize dietary conditions among groups. After these 
two weeks, a staff member who was not involved in the study blindly allocated the 
subjects to one of the three intervention diets: a high SFA-diet, a high MUFA-diet, or 
a Mediterranean diet. This was done by randomization with stratification for gender 
and agreement to participate in the additional clamp studies. Couples were allocated 
to the same intervention diet.
The high SFA-diet had the same composition as the run-in diet. The high MUFA-diet 
was rich in refined olive oil and contained a higher percentage of energy from MUFA 
and a lower percentage of SFA than the high SFA-diet (Table 5.1). The high MUFA-diet 
had similar contents of carbohydrates, protein, and dietary fibre as the high SFA-diet. 
The Mediterranean diet was rich in extra-virgin olive oil and had similar contents 
of MUFA and SFA, higher intakes of vegetables and fruits and lower intakes of dairy 
products and meat than the high MUFA-diet. Subjects consumed the intervention 
diets for eight weeks.
Before the start of the study the habitual energy intake of individual subjects was 
estimated by a food-frequency questionnaire [96]. Subjects received foods covering 
90% of their energy needs. Each subject was obliged to choose additional foods for the 
remaining 10% of energy needs from a so called free-choice list containing food items 
low in fat and dietary fibre. The diets were provided as a 14 day menu cycle. Subjects 
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consumed their hot meal on workdays at Wageningen University under supervision 
of the researchers. Breakfast, bread meals, snacks, beverages, and all meals for the 
weekends were provided in take-home packages. Subjects were carefully instructed 
how to prepare the take-home meals.
Some foods were exclusively provided in the Mediterranean diet: fatty fish (3 servings/
week), unrefined-grain products, nuts (15 g/day), legumes (40 g/day), and red wine 
(1 glass/day). Alcohol was not provided in the high MUFA and SFA-diet but subjects 
were allowed to drink alcohol as free-choice items except for red wine or red-port 
wine. Maximum alcohol consumption in all groups was 2 glasses/day. Subjects were 
asked to maintain their usual pattern of physical activity, smoking habits, and use of 
oral contraceptives throughout the study. They recorded any signs of illness, used 
medications, food items chosen from the free-choice list, and deviations from dietary 
guidelines in diaries.
Body weight was measured twice a week and energy intake was adjusted in case of 
weight change. When subjects had incidental increased energy requirements, e.g. 
because of sports, a bread bun (500 kJ/bun) was provided with the same relative 
macronutrient composition as the intervention diet of the subject. Duplicate portions 
of an average energy level of 11 MJ of each intervention diet were collected daily, 
pooled by intervention group and analysed for energy, macronutrients, fatty acids, and 
dietary fibre composition after the study. The average energy and nutrient content of 
the reported free-choice items per intervention group was calculated using the Dutch 
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Table 5.1  Mean daily intake of energy and nutrients of subjects on the high SFA, high 
MUFA, or Mediterranean diets
Abbreviations: Saturated fatty acids (SFA), monounsaturated fatty acids (MUFA), polyunsaturated fatty acids 
(PUFA), percentage of total energy intake (energy-%)
Values are based on chemical analysis of complete duplicate diets plus the calculated contribution of free-
choice items. The duplicate diets were collected daily and pooled for each intervention group.
1 Red wine was provided in the Mediterranean diet group. Alcohol consumption (maximum 2 glasses/day) was 
allowed in the other diets as well, with the exception of red wine.
High SFA High MUFA Mediterranean
Energy, MJ/day 10.7 10.4 10.3
Total fat, energy-% 36.8 39.9 40.2
SFA 19.2 10.9 10.7
MUFA 10.7 20.3 21.4
PUFA 5.4 7.0 6.5
n-3 PUFA 0.4 0.6 0.8
n-6 PUFA 5.0 6.4 5.6
Protein, energy-% 13.5 11.4 14.5
Carbohydrates, energy-% 47.3 46.4 41.1
Dietary fibre, g/MJ 2.4 2.4 3.6
Cholesterol, mg/MJ 25.7 24.2 25.6
Alcohol1, energy-% 2.3 2.2 4.2
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food-composition table (NEVO, 2006). The values of the duplicate portions and the 
free-choice items were combined (Table 5.1).
An intervention study that compared the effects of a high MUFA-diet with a high 
SFA-diet observed a difference of 17.6 pmol/L in insulin concentration (personal 
communication with Perez-Jimenez) [40]. In our power calculations, we expected 
a differential change in fasting insulin concentration of 8.5 pmol/L and a standard 
deviation of the within-group difference of 9.0 pmol/L. We expected a differential 
change in total cholesterol concentrations of 0.52 mmol/L and a standard deviation 
of the within-group difference of 0.47 mmol/L [97]. A sample size of n=20 per 
intervention group was required to detect differential changes in fasting insulin and 
total cholesterol concentrations, with a power of 80% at a significance level of 0.05, 
taking into account a drop out of 10%.
Measurements
Four blood samples were drawn, two at baseline (at the end of the run-in period; day 
10 or 11, and day 15 or 16) and two at the end of the study (day 65 or 66, and day 70 
or 71). We took the mean of two measurements sampled at baseline and at the end 
of the study. Venous blood was taken from the antecubital vein after an overnight 
fast. All serum samples were kept at -80oC until further analysis within one run. 
Concentrations of total- and HDL-cholesterol and triglycerides were measured 
by a Dimension Clinical Chemistry System (Dade Behring Inc, USA) by Stichting 
Huisartsenlaboratorium Oost, Velp, the Netherlands. LDL-cholesterol was calculated 
with the formula of Friedewald [98]. Concentrations of insulin and C-peptide 
were measured using an immunometric assay (Bayer diagnostics, Mijdrecht, the 
Netherlands) by the Laboratory of Endocrinology, VU University, Amsterdam, the 
Netherlands. Blood for glucose measurement was collected in NaF tubes. These tubes 
were stored for a maximum of 24 h at 2-8oC, until plasma glucose was measured by 
Stichting Huisartsenlaboratorium Oost, Velp, the Netherlands, on the Synchron LX20 
system using hexokinase and glucose-6-phosphate dehydrogenase (Glucose reagent, 
Beckman Coulter, Fullerton, USA). Homeostatic model assessment (HOMA-IR) was 
used for assessing insulin sensitivity from fasting glucose and insulin concentrations 
(http://www.dtu.ox.ac.uk/).
Anthropometric measurements were performed at baseline and at the end of the study 
by the same researcher. Body weight of subjects wearing indoor clothing without 
footwear was measured to the nearest 0.1 kg using a digital weighing scale (Seca, 
Bascule MT, USA). Waist circumference was measured in duplicate midway between 
the lower rib margin and the iliac crest, accurate to 0.5 cm, using a non stretchable 
tape. Height was measured to the nearest 0.1 cm using a microtoise.
Thirty subjects underwent a hyperinsulinemic-euglycemic clamp to assess stimulated 
insulin sensitivity [99]. Clamp measurements were performed during the period from 
two weeks before until the first week of the run-in period and during the last three 
weeks of the intervention period in Hospital Gelderse Vallei, Ede, the Netherlands. 
Glucose was clamped at a glucose concentration of 5 mmol/L by titrating a variable-
rate glucose infusion (20%) against a fixed-rate infusion of soluble insulin (Actrapid, 
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100 IU/ml, at the rate of 40 mIU/ml/min/m2). The glucose infusion rate was computed 
based on measurements of glucose concentrations by a HemoCue blood analyser on 
five-minute intervals throughout the clamp. After reaching steady state for at least 30 
minutes, the degree of insulin sensitivity (M-value) was determined as the amount 
of glucose necessary to maintain the blood glucose concentration divided by the fat-
free mass (FFM). FFM was measured by air-displacement plethysmography in the 
Bod Pod [100].
Statistics
Differential changes between the high MUFA-diet and the high SFA-diet and between 
the Mediterranean diet and the high MUFA-diet were examined using analysis 
of covariance with predefined contrasts. Group differences in outcome measures 
measured after eight weeks of interventions were adjusted for each subjects baseline 
value of the outcome measure [101], gender and participation in clamp measurements 
[102]. We analysed the data using SAS 9.1.3 (SAS Institute Inc., Cary, NC, USA). 
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Figure 5.1  Flow diagram of the study.
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Results
Fifty-seven out of 60 subjects completed the trial (Figure 5.1). One subject withdrew 
during the run-in period because of illness and two subjects withdrew during the 
intervention period because of personal reasons. Subjects in the three intervention 
groups were comparable in their baseline concentrations of the outcome measures of the 
study (Table 5.2). Subjects reported no important deviations from the study protocol. 
The high MUFA-diet reduced total and LDL-cholesterol concentrations and the 
total cholesterol/HDL-cholesterol ratio compared with the SFA-diet (Table 5.3). The 
Mediterranean diet did not reduce total and LDL-cholesterol but increased HDL-
cholesterol concentration and reduced the total cholesterol/HDL-cholesterol ratio 
compared with the high MUFA-diet. Changes in triglyceride concentration were 
not significantly different between the high MUFA-diet and the SFA-diet, but the 
Mediterranean diet tended to reduce triglycerides compared with the high MUFA-
diet.
The change in insulin concentration was not significantly different between the high 
MUFA-diet and the high SFA- diet nor between the Mediterranean diet and the high 
MUFA-diet. Also no differential changes in C-peptide, HOMA-IR and glucose were 
Table 5.2  Baseline characteristics of the 57 subjects completing the study
Abbreviations: Saturated fatty acids (SFA), monounsaturated fatty acids (MUFA), homeostatic model 
assessment insulin resistance (HOMA-IR).
1 Median (interquartile range).
Mean (sd)
High SFA
N=19
High MUFA
N=18
Mediterranean
N=20
Age, years 52.0 (7.2) 58.9 (5.1) 56.8 (6.0)
Men, N (%) 8 (42) 8 (44) 8 (40)
Body weight, kg 79.9 (12.9) 79.2 (14.0) 84.0 (14.6)
Body mass index, kg/m² 26.1 (2.7) 27.6 (5.5) 28.3 (5.9 )
Waist circumference, cm
Men 103.1 (8.1) 99.7 (7.8) 103.4 (11.5)
Women 88.3 (3.6) 95.4 (16.6) 95.8 (18.1)
Serum insulin1, pmol/L 44.0 (35.4, 51.0) 44.1 (32.8, 47.6) 42.5 (31.1, 53.8)
Serum C-peptide1, nmol/L 0.53 (0.46, 0.60) 0.48 (0.41, 0.61) 0.56 (0.42, 0.73)
Glucose, mmol/L 5.4 (0.4) 5.2 (0.3) 5.4 (0.4)
HOMA-IR1 0.81 (0.68, 0.98) 0.84 (0.62, 0.91) 0.82 (0.59, 1.04)
Total cholesterol, mmol/L 5.68 (1.08) 5.84 (0.65) 5.61 (0.99)
LDL-cholesterol, mmol/L 3.99 (0.94) 3.95 (0.68) 3.78 (0.94)
HDL-cholesterol, mmol/L 1.32 (0.30) 1.41 (0.38) 1.35 (0.49)
Triglyceride1, mmol/L 0.90 (0.65, 1.40) 1.20 (0.90, 1.50) 1.23 (0.73, 1.60)
Total cholesterol/HDL-cholesterol ratio 4.49 (1.16) 4.41 (1.19) 4.59 (1.40)
Users of oral contraceptives, N (%) 0 (0) 0 (0) 0 (0)
Smokers, N (%) 4 (21) 0 (0) 2 (10)
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observed. In the sub-group of 30 subjects who participated in the clamp study, the 
high MUFA-diet did not change insulin sensitivity compared with the SFA-diet (+2.12 
μmol/min/kgFFM, 95%CI -9.77; 14.00) and the Mediterranean did not affect insulin 
sensitivity differently than the high MUFA-diet (+1.24 μmol/min/kgFFM, 95%CI 
-10.83; 13.32).
Although body weight and waist circumference decreased slightly during the 
intervention period, they were not significantly different between the three intervention 
groups. Additional adjustment for changes in body weight and waist circumference led 
to similar conclusions for all outcome measurements (data not shown).
Discussion 
In our controlled-feeding trial, a high MUFA-diet and a Mediterranean diet did not 
affect insulin sensitivity compared with a high SFA-diet. However, the high MUFA-
diet reduced total- and LDL-cholesterol concentrations and total cholesterol/HDL-
cholesterol ratio. In addition, the Mediterranean diet increased HDL-cholesterol and 
reduced the ratio of total cholesterol/HDL-cholesterol.
Our study is the first to compare the effects of a Dutch high MUFA-diet with a 
Mediterranean diet with similar fatty-acid composition on serum lipids and insulin 
sensitivity. Strengths of our study are a low number of drop outs (n=3) and a high 
compliance. A high compliance was demonstrated by the effect size of the high MUFA-
diet on total cholesterol that was similar to that reported in previous controlled-feeding 
trials [39, 97]. Other strengths are the methods we used to measure insulin sensitivity. 
Table 5.3  Differences between assessed variables after 8 weeks of intervention diet
Abbreviations: saturated fatty acids (SFA), monounsaturated fatty acids (MUFA), homeostatic model assessment 
insulin resistance (HOMA-IR).
1 Adjusted for baseline levels, gender and participating in clamp measurements (yes/no).
Outcome variables after 8 weeks of intervention1 
Mean (se)
Differences between groups1
Mean (95%CI)
High SFA
N=19
High MUFA
N=18
Mediterranean
N=20
MUFA – SFA Mediterranean – MUFA
Serum insulin, pmol/L 39.7 (2.6) 45.6 (2.7) 40.8 (2.5) 5.9 (-1.5; 13.4) -4.9 (-12.2; 2.5)
HOMA-IR 0.76 (0.05) 0.86 (0.05) 0.78 (0.05) 0.11 (-0.04; 0.25) -0.09 (-0.23; 0.06)
Serum C-peptide, nmol/L 0.52 (0.02) 0.55 (0.02) 0.51 (0.02) 0.03 (-0.03; 0.08) -0.03 (-0.09; 0.02)
Glucose, mmol/L 5.33 (0.06) 5.25 (0.06) 5.28 (0.06) -0.08 (-0.25; 0.08) 0.03 (-0.14; 0.20)
Total cholesterol, mmol/L 5.63 (0.11) 5.22 (0.12) 5.19 (0.11) -0.41 (-0.74; -0.09) -0.03 (-0.35; 0.29)
LDL-cholesterol, mmol/L 3.90 (0.09) 3.52 (0.10) 3.42 (0.09) -0.38 (-0.65; -0.11) -0.09 (-0.36; 0.17)
HDL-cholesterol, mmol/L 1.29 (0.03) 1.30 (0.03) 1.39 (0.03) 0.01 (-0.08; 0.10) 0.09 (0.00; 0.18)
Triglyceride, mmol/L 1.17 (0.05) 1.12 (0.05) 1.00 (0.04) -0.05 (-0.18; 0.08) -0.12 (-0.25; 0.01)
Total cholesterol/HDL-
cholesterol ratio
4.58 (0.08) 4.27 (0.08) 3.88 (0.08) -0.30 (-0.54; -0.07) -0.39 (-0.62; -0.16)
Body weight, kg 79.6 (0.3) 80.4 (0.3) 79.8 (0.3) 0.8 (-0.1; 1.8) -0.6 (-1.6; 0.3)
Waist circumference, cm 94.5 (0.8) 96.2 (0.9) 94.8 (0.8) 1.7 (-0.8; 4.1) -1.4 (-3.8; 1.0)
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We measured insulin sensitivity by insulin concentration and with the golden-standard 
hyperinsulinemic-euglycemic clamp procedure in half of the subjects. We also increased 
the precision of the measurements of insulin and serum lipid concentrations by taking 
the mean of two measurements sampled on two days, both at baseline and at the end 
of the study.
Regarding serum lipids, we found beneficial effects of the high MUFA-diet that 
correspond with the predicted differences between a high MUFA-diet and a SFA-diet 
using the model developed by Mensink et al. [39]. As this model is based on a meta-
analysis of 60 controlled trials, this demonstrates the validity of our study.
Other Mediterranean diet intervention studies showed beneficial effects on serum 
lipids [30, 31]. However, none of these studies was able to disentangle the effects of 
separate Mediterranean components. Among these components, dietary fibre [95] 
and nuts [37] are expected to reduce concentrations of total- and LDL-cholesterol 
and triglycerides. The Mediterranean diet contained more dietary fibre and nuts 
than the high MUFA-diet, however it did not result in larger reductions in total- and 
LDL-cholesterol and triglyceride concentrations. This suggests that these additional 
effects are small, at least for total- and LDL-cholesterol. Regarding triglycerides our 
findings point at a stronger reduction with the Mediterranean diet compared with 
the high MUFA-diet.
The additional value of the Mediterranean diet compared with the MUFA-diet was 
shown for HDL-cholesterol and the total cholesterol/HDL-cholesterol ratio. These 
effects may be related to the higher consumption of alcohol and extra-virgin olive 
oil in the Mediterranean diet. One gram of alcohol was predicted to increase HDL-
cholesterol by 0.003 mmol/L [38]. Alcohol intake in the Mediterranean group was 2 
energy-% (7 gram alcohol) higher than in the high MUFA-group. This would have 
resulted in a difference of 0.02 mmol/L in HDL-cholesterol between the two groups. 
Extra-virgin olive oil is richer in polyphenols than refined olive oil that was used in the 
high MUFA-diet. When a diet with high-polyphenol olive oil was compared with the 
effect of a diet with low-polyphenol olive oil, the differential change in HDL-cholesterol 
was 0.02 mmol/L, after 3 weeks [103]. However, the sum of predicted changes (0.02 
mmol/L for alcohol and 0.02 mmol/L for polyphenols from olive oil) can explain only 
half of the observed change in HDL-cholesterol (0.09 mmol/L). This suggests that other 
components of the Mediterranean diet play a role in improving HDL-cholesterol.
The triglyceride/HDL-cholesterol ratio was suggested to be an indicator of insulin 
resistance [104]. In our study, we were able to demonstrate favourable effects on serum 
lipids especially for HDL-cholesterol and triglycerides with the Mediterranean diet. 
However, we did not find an effect on insulin sensitivity. Rather, our MUFA-diet tended 
to increase insulin concentrations. Our lack of effect by the MUFA-diet is compatible 
with the results from Lovejoy et al. [105], but not with the reductions in fasting insulin 
by MUFA in the study of Perez-Jimenez [40] and the KANWU study [41]. Although 
design issues including study duration and diet contrast might partly be responsible, 
these can be rebutted. The duration of our study was not as long as that of other studies 
showing an effect of the Mediterranean diet on insulin sensitivity [30, 31]. However, 
our study was almost twice as long as the study of Perez-Jimenez, which showed an 
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effect of a high MUFA-diet compared with a high SFA-diet [40]. The contrast in MUFA 
intake between the high MUFA-diet and the high SFA-diet in our study (9 energy-%) 
was smaller than in the study of Perez-Jimenez (14 energy-%) but larger than in the 
KANWU study (8 energy-%) that showed an improvement in insulin sensitivity [41]. 
Also other Mediterranean diet intervention studies with smaller contrasts in MUFA 
intake than in our study increased insulin sensitivity [30, 31]. Thus, the contrasts in 
MUFA intake between the intervention diets in our study were large enough to be 
able to show an effect on insulin sensitivity. 
The results of a subgroup analysis within the KANWU study suggested that the effect 
of replacing SFA with MUFA was not present in the context of a high fat diet (>37 
energy-%) [41]. An observational study also reported an interaction between total 
fat intake <37 energy-% and fatty acid profile in association with markers of insulin 
sensitivity [106]. Total fat intake in our study was around that amount and this might 
explain the absence of an effect on insulin sensitivity. The KANWU study had a wide 
variation in total fat intake with 95% of their subjects in the range 29-45 energy-% and 
hence was able to identify this post-hoc difference, while our study was fully controlled 
with a much smaller range. Therefore, it remains an option that needs to be explored, 
although the only other study on replacing SFA with MUFA against a relatively low 
total fat background gave a null result [105].
Another explanation for the absence of an effect in our study might be that subjects 
were on average insulin sensitive. One could speculate that our subjects would be less 
responsive to dietary changes than less insulin sensitive subjects. However, intervention 
studies showing an effect of a high MUFA-diet or a Mediterranean diet were performed 
not only in subjects that were less insulin sensitive than our subjects [30, 31], but also 
in healthy subjects [40, 41].
In conclusion, replacing a high SFA-diet with a high MUFA-diet improved serum 
lipids. Additionally, our study showed a beneficial effect of a Mediterranean diet 
on HDL-cholesterol and total cholesterol/HDL-cholesterol ratio. This implies that 
persons who adopt a Mediterranean diet could improve their serum lipids and hence 
their cardiovascular risk. We did not observe an effect of a high MUFA-diet or a 
Mediterranean diet on insulin sensitivity. The additional beneficial effect of the full 
Mediterranean pattern on insulin sensitivity requires further attention. 
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Abstract
Objective: To compare effects of replacing a diet high in saturated fatty acids (SFA) with 
a diet high in monounsaturated fatty acids (MUFA) or a Mediterranean diet on apolipo-
protein A-I and B (apo A-I and apo B).
Design: Controlled-feeding trial, in 60 non-diabetics (40-65y) with mild abdominal 
obesity. Subjects received a high SFA-diet (SFA 19% of total energy intake (energy-%)), 
a high MUFA-diet (MUFA 20 energy-%) or a Mediterranean diet (MUFA 21 energy- %) 
for eight weeks.
Results: The high MUFA-diet and the Mediterranean diet did not affect apo A-I level 
compared with the high SFA-diet, despite significant changes in HDL-cholesterol by the 
Mediterranean diet. Compared with the high SFA-diet, the high MUFA-diet reduced 
apo B level (-0.08 g/L, 95%CI -0.15; -0.01) and the apo B/apo A-I ratio (-0.07 g/L, 95%CI 
-0.14; -0.01). The Mediterranean diet further reduced apo B level and the apo B/apo A-I 
ratio, however compared with the high MUFA-diet these reductions were not statisti-
cally significant (apo B -0.05 g/L, 95%CI -0.11; 0.02, apo B/apo A-I ratio 0.05, 95%CI 
-0.11; 0.02).
Conclusions: Replacing a high SFA-diet with a high MUFA or a Mediterranean diet did 
not affect apo A-I levels. The Mediterranean diet tended to improve apo B levels and the 
apo B/apo A-I ratio more than the high MUFA-diet.
Introduction
A recent controlled-feeding trial showed that replacing a diet high in saturated fatty 
acids (SFA) with a diet high in monounsaturated fatty acids (MUFA) or a Mediterranean 
diet decreased total cholesterol, LDL-cholesterol and triglyceride concentrations [107]. 
In addition, this trial showed that a Mediterranean diet increased HDL-cholesterol 
more than the diet high in MUFA did. Although not statistically significant, the 
effect of the Mediterranean diet on triglyceride concentrations was almost twice as 
large as the effect of the diet high in MUFA. This implies that the beneficial effect 
of a Mediterranean diet on HDL-cholesterol and triglyceride concentrations is not 
(only) due to the high MUFA content of a Mediterranean diet but to the cumulative 
effect of the Mediterranean components. A Mediterranean diet may cause a shift to a 
more favourable serum lipid profile. Accumulating evidence indicates that the ratio 
of apolipoprotein B (apo B)/ apolipoprotein-A-I (apo A-I) is superior to any of the 
cholesterol ratios for quantifying the lipoprotein related risk of cardiovascular disease 
[108]. This may be partly explained by the fact that apo B does not only reflect the 
number of LDL particles but also that of other atherogenic particles such as VLDL, 
IDL, and Lp(a). Therefore, we studied the effects of a Mediterranean diet on the apo 
B/apo A-1 ratio. In addition, we studied the effects of a Mediterranean diet on the apo 
A-I/HDL-cholesterol ratio and the log (triglyceride/HDL-cholesterol) ratio, which 
may reflect HDL particles size [109]. Increased particle size might also be a marker 
of lower cardiovascular disease risk [110]. 
Subjects and Methods
We carried out a controlled-feeding study [107], which included 60 non-diabetic 
subjects aged 40-65 years with a BMI ≥25 kg/m2 or a waist circumference ≥94 cm for 
men and ≥80 cm for women. All subjects received a Western-style diet high in SFA 
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for a two weeks run-in period. After these two weeks, subjects were allocated to one 
of the three intervention diets: a high SFA-diet, a high MUFA-diet or a Mediterranean 
diet. This was done by randomization with stratification for gender and agreement 
to participate in additional clamp studies. Each subject consumed their diet for 8 
weeks.
The high SFA-diet had the same composition as the run-in diet i.e. SFA (19.2 of total 
energy intake (energy-%)) and MUFA (10.7 energy-%). The high MUFA-diet contained 
a higher percentage of energy from MUFA (20.3 energy-%) and a lower percentage of 
SFA (10.9 energy-%) than the high SFA-diet. The high MUFA-diet was comparable 
with the high SFA-diet with regard to the composition of carbohydrates, protein, and 
dietary fibre. The Mediterranean diet had similar contents of MUFA (21.4 energy-%) 
and SFA (10.7 energy-%) as the high MUFA-diet. The Mediterranean diet consisted 
of a higher intake of vegetables, fruits, and a lower intake of dairy products, meat, and 
meat products than the high MUFA-diet. Some foods were exclusively provided in the 
Mediterranean diet, such as fatty fish (3 servings per week), unrefined grain products, 
nuts (15 g/day), legumes (40 g/day), and red wine (1 glass/day).
Fasting venous blood was taken at the end of the run-in period and at the end of the 
study. Concentrations of total and HDL-cholesterol and triglyceride were measured by 
a Dimension Clinical Chemistry System (Dade Behring Inc, USA). LDL-cholesterol 
was calculated with the formula of Friedewald et al. [98]. Apo A-I and apo B were 
measured by immunoturbidimetry (Synchron LX® Systems).
Differential changes between the high MUFA-diet and the high SFA-diet and between 
the Mediterranean diet and the high MUFA-diet were examined using analysis of 
covariance (ANCOVA) with predefined contrasts. Group differences in outcome 
measures determined after eight weeks of interventions, were adjusted for each 
participant’s baseline value of the outcome measure [101], gender and participation 
in clamp measurements [102].
Results and discussion
Of the 60 participants enrolled in the study, 57 completed the trial. We found no 
substantial differences between the intervention groups in serum lipid concentrations 
or apo A-I, apo B or the apo B/apo A-I ratio at baseline (Table 6.1). The high MUFA-
diet significantly reduced apo B level as well as the apo B/apo A-I ratio compared with 
the high SFA diet, reflecting significant reductions in LDL-cholesterol concentrations 
(Table 6.2). The Mediterranean diet further reduced apo B level and apo B/apo A-I ratio, 
however compared with the high MUFA-diet these reductions were not statistically 
significant (apo B p=0.18; apo B/apo A-I ratio p=0.14). Changes in apo A-I were not 
different between the groups despite a clear increase in HDL-cholesterol with the 
Mediterranean diet. The apo A-1/HDL cholesterol ratio and the log (triglyceride/
HDL-cholesterol) ratio significantly decreased with the Mediterranean diet compared 
with the high MUFA-diet.
Our study suggests that a Mediterranean diet reduced apo B and the apo B/apo A-I 
ratio more than the high MUFA diet did. Although the additional reductions of this 
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Table 6.1  Baseline characteristics of the 57 participants completing the study
Abbreviations: Saturated fatty acids (SFA), monounsaturated fatty acids (MUFA).
1 Median (interquartile range).
Mean (sd)
High SFA
N=19
High MUFA
N=18
Mediterranean
N=20
Age, years 52.0 (7.2) 58.9 (5.1) 56.8 (6.0)
Men, N (%) 8 (42) 8 (44) 8 (40)
Body mass index, kg/m² 26.1 (2.7) 27.6 (5.5) 28.3 (5.9)
Waist circumference, cm
Men 103.1 (8.1) 99.7 (7.8) 103.4 (11.5)
Women 88.3 (3.6) 95.4 (16.6) 95.8 (18.1)
Total cholesterol, mmol/L 5.68 (1.08) 5.84 (0.65) 5.61 (0.99)
LDL-cholesterol, mmol/L 3.99 (0.94) 3.95 (0.68) 3.78 (0.94)
HDL-cholesterol, mmol/L 1.32 (0.30) 1.41 (0.38) 1.35 (0.49)
Triglyceride1, mmol/L 0.90 (0.65, 1.40) 1.20 (0.90, 1.50) 1.23 (0.73, 1.60)
Log (triglyceride/HDL-cholesterol ratio) -0.13 (0.27) -0.06 (0.22) -0.05 (0.38)
Apolipoprotein A-I1, g/L 1.01 (0.89, 1.10) 1.06 (1.03, 1.10) 1.04 (0.92, 1.18)
Apolipoprotein B, g/L 1.09 (0.26) 1.09 (0.17) 1.08 (0.26)
Apolipoprotein B/apolipoprotein A-I ratio 1.10 (0.26) 1.04 (0.25) 1.05 (0.31)
Apolipoprotein A-1/HDL-cholesterol ratio1 0.80 (0.67, 0.89) 0.78 (0.69, 0.84) 0.83 (0.67, 0.99)
Table 6.2  Differences between assessed variables after 8 weeks of intervention diet
Abbreviations: saturated fatty acids (SFA), monounsaturated fatty acids (MUFA).
1 Adjusted for baseline levels, gender and participating in clamp measurements (yes/no).
Outcome variables after 8 weeks of intervention1 
Mean (se)
Differences between groups1
Mean (95%CI)
High SFA
N=19
High MUFA
N=18
Mediterranean
N=20
MUFA – SFA Mediterranean – MUFA
Total cholesterol, mmol/L 5.63 (0.11) 5.22 (0.12) 5.19 (0.11) -0.41 (-0.74; -0.09) -0.03 (-0.35; 0.29)
LDL-cholesterol, mmol/L 3.90 (0.09) 3.52 (0.10) 3.42 (0.09) -0.38 (-0.65; -0.11) -0.09 (-0.36; 0.17)
HDL-cholesterol, mmol/L 1.29 (0.03) 1.30 (0.03) 1.39 (0.03) 0.01 (-0.08; 0.10) 0.09 (0.00; 0.18)
Triglyceride, mmol/L 1.17 (0.05) 1.12 (0.05) 1.00 (0.04) -0.05 (-0.18; 0.08) -0.12 (-0.25; 0.01)
Total cholesterol/HDL-
cholesterol ratio
4.58 (0.08) 4.27 (0.08) 3.88 (0.08) -0.30 (-0.54; -0.07) -0.39 (-0.62; -0.16)
Log (triglyceride/HDL-
cholesterol ratio)
-0.06 (0.02) -0.10 (0.02) -0.17 (0.02) -0.04 (-0.10; 0.01) -0.07 (-0.12; -0.01)
Apolipoprotein A-1, g/L 1.06 (0.01) 1.07 (0.01) 1.06 (0.01) 0.01 (-0.03; 0.05) 0.00 (-0.04; 0.04)
Apolipoprotein B, g/L 1.11 (0.02) 1.03 (0.02) 0.98 (0.02) -0.08 (-0.15;-0.01) -0.05 (-0.11; 0.02)
Apolipoprotein B/
apolipoprotein A-1 ratio
1.06 (0.02) 0.99 (0.02) 0.94 (0.02) -0.07 (-0.14; -0.01) -0.05 (-0.11; 0.02)
Apolipoprotein A-1/HDL-
cholesterol ratio
0.85 (0.01) 0.85 (0.01) 0.80 (0.01) 0.00 (-0.03; 0.04) -0.06 (-0.10; -0.02)
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diet are not statistically significant, we consider the effects clinically relevant. The effect 
size of the Mediterranean diets was almost twice as large as the effect size of the high 
MUFA-diet. Reduced apo B levels indicate a smaller number of atherogenic particles 
including LDL, VLDL, IDL, and Lp(a); and this implies reduced cardiovascular risk. 
Ambring et al. also found that a Mediterranean diet reduced apo B levels compared 
with a typical Swedish diet [32].
The Mediterranean diet significantly increased HDL-cholesterol concentration and 
decreased the apo A-1/HDL-cholesterol ratio compared with the high-MUFA diet; 
however, the apo A-I levels were not different between the two diets. These findings 
suggest that a Mediterranean diet has an effect on HDL particle size, with a shift towards 
larger more cholesterol-rich HDL2 particles [111]. In addition, the log (triglyceride/
HDL-cholesterol) ratio was shown to be negatively correlated with the proportion of 
HDL2 particles [109]. As the Mediterranean diet decreased the log (triglyceride/HDL-
cholesterol) ratio compared with the high MUFA diet, this also points at an increased 
proportion of HDL2 particles.
In conclusion, our results suggest that compared with a high-MUFA diet a 
Mediterranean dietary pattern may reduce apo B levels and hence reduce cardiovascular 
risk even further. In addition, an increase in HDL2 particles is suggested by the data, 
which may be important in reducing cardiovascular risk as well.
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Discussion
In this thesis, we studied whether a Mediterranean diet favourably affects the metabolic 
syndrome. According to our own observations this syndrome is highly prevalent in 
the Netherlands as it already affected approximately one million Dutch adults below 
60 years of age in the 1990s. Therefore, the main findings of our observational studies 
and intervention study may have significant implications for public health. In this 
chapter, we will first summarise and critically address our own findings in view of the 
used methodology and findings from the literature. It is only after these reflections 
that we can present our overall conclusion, identify research needs and address the 
impact of a Mediterranean diet on public health. 
Main findings  
In both the SENECA study and the intervention study we find support for the 
hypothesis that a Mediterranean diet has a beneficial effect on two characteristics of 
the metabolic syndrome, namely on HDL-cholesterol and triglyceride concentrations 
(chapters 3 and 5). In addition, the findings of the SENECA study suggest that subjects 
with good adherence to a Mediterranean diet had a lower prevalence of the metabolic 
syndrome and a smaller waist circumference than subjects with poor adherence 
(chapter 3). In the CoDAM study (chapter 4), we did not find these associations. 
Neither did we find support for the hypothesis that a Mediterranean diet would improve 
glucose concentration, insulin sensitivity or blood pressure. Table 7.1 summarises the 
main findings of the two observational studies (SENECA study and CoDAM study) 
and the intervention study as presented in this thesis. 
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Table 7.1  Main findings
Characteristics of the metabolic syndrome Observational studies Intervention study
SENECA
N=1254
CoDAM
N=450 N=60
Metabolic syndrome  – na
HDL-cholesterol  – 
Triglyceride  – 
Abdominal obesity  – na
Glucose – – –
Blood pressure na – na
Abbreviations: not applicable (na).
 /   Beneficial association/effect.
         Suggested beneficial association/effect (not significant).
–         No beneficial association/effect.
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Mediterranean diet score
tIn our observational studies, we examined dietary patterns rather than individual 
nutrients or food groups in relation to the metabolic syndrome. There are several 
reasons for studying dietary patterns. Meals are eaten with complex combinations of 
nutrients that may be interactive or synergistic [112]. As many nutrients are highly 
correlated, it is difficult to study their separate effects. In addition, the effect of a 
single nutrient may be too small to detect an effect whereas the cumulative effect of 
multiple nutrients in a dietary pattern may be large enough. In order to characterize 
the dietary pattern we used the Mediterranean diet score developed by Trichoupoulou 
et al. [25], which aims to assess the diet’s degree of resemblance to a Mediterranean 
diet. This Mediterranean diet score includes nine Mediterranean components and uses 
sex-specific median intakes as cut-off values for the components: monounsaturated 
fatty acids (MUFA)/saturated fatty acids (SFA) ratio, cereals, legumes, fruits and nuts, 
vegetables, fish, dairy products, meat and poultry. As population-specific cut-off values 
are used, it has to be established to what extent such score truly reflects adherence 
to a Mediterranean type of diet. For example, in a Mediterranean diet that contains 
abundant olive oil a MUFA/SFA ratio larger than one is expected. However, in our 
studies we found median MUFA/SFA ratios smaller than one. We compared the 
cut-off values used in the SENECA and the CoDAM study with the mean intake of 
Mediterranean components by Greek men participating in the seven countries study 
(Crete) in 1960-1965, which resembles a traditional Mediterranean diet (Table 7.2).
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Table 7.2  Comparison of the intakes of components of the Mediterranean diet score in 
men participating in the seven countries study (Crete, Greece), the SENECA and the CoDAM 
study
Abbreviations: monounsaturated fatty acids (MUFA), saturated fatty acids (SFA), not applicable (na).
1 After adjustment for energy consumed (10.5 MJ). 
2 Also includes potatoes.
3 Also includes nuts and seeds.
4 Includes no nuts.
Components of the 
Mediterranean diet score
Mean intake1
Crete (1960-1965)
Median intake1
(interquartile range)
SENECA
Median intake1
(interquartile range) 
CoDAM
MUFA/SFA ratio 3.7 0.98 (0.83, 1.23) 0.84 (0.78, 0.92)
Vegetables, g/day 180 3012 (225, 411) 138 (101, 185)
Legumes, g/day 28 43 (0, 18) 6 (2, 13)
Fruits and nuts, g/day 4374 201 (110, 336) 195 (108, 300)
Cereals, g/day 5652 230 (182, 304) 4192 (357, 482)
Fish, g/day 17 29 (14, 59) 10 (4, 16)
Meat and poultry, g/day 33 135 (99, 173) 149 (110, 193)
Dairy products, g/day 234 323 (177, 502) 248 (137, 417)
Alcohol (10-50g/day), N (%) na 271 (43) 135 (49)
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The MUFA/SFA ratio and the intakes of legumes, fruits and cereals in Crete were higher 
than those in our studies, while the intakes of meat and poultry and dairy products were 
lower. Using Cretan cut-off values would better discriminate between subjects with 
good and poor adherence to a traditional Mediterranean diet. However, components 
with ranges fully or largely above or below these cut-off values will not contribute to 
the discriminating power of the Mediterranean diet score [113]. As a consequence, 
this would result in few subjects with good adherence to a traditional Mediterranean 
diet in our studies and we would not have had power to find associations between a 
Mediterranean diet and the metabolic syndrome.
Although the cut-off values of neither the SENECA nor the CoDAM study are close 
to those of the Cretan study, the cut-off values in the SENECA study suggest that the 
diets of the European elderly were on average more Mediterranean than the diets of 
the subjects in the CoDAM study. Especially the cut-off values for MUFA/SFA ratio 
and fish intake were substantially higher in the SENECA study than in the CoDAM 
study. It may be due to these differences that we found more associations between a 
Mediterranean diet and the characteristics of the metabolic syndrome in the SENECA 
study than in the CoDAM study.
Controlling dietary intakes in intervention studies
Although the Mediterranean diet score implies that each of its components is equally 
important, we gave attention to the importance of MUFA intake in relation to the 
metabolic syndrome by comparing the effects of replacing a high SFA-diet with a high 
MUFA-diet or a Mediterranean diet. Such a comparative approach was also used in six 
other intervention studies (Table 7.3), but comparisons are hampered by differences 
or constraints in control diets, control of dietary intake, and weight maintenance.
First, most of these studies did not use a high SFA-diet as control diet but either a low 
fat diet [31, 60, 82, 114] or a prudent diet [30]. Second, in these studies dietary intake 
was not fully controlled by providing all foods. Instead, subjects were advised to eat a 
Mediterranean diet or a control diet. Only in the study of Ambring et al. [32] dietary 
intake was controlled by providing 60% of the daily energy needs. As a consequence 
of incomplete control of dietary intake in the Medi-RIVAGE study [114], the diet of 
subjects in the Mediterranean group was similar in macronutrient composition to the 
diet of subjects in the control group, which probably explains the lack of a differential 
effect on characteristics of the metabolic syndrome.
A third major difference between our controlled-feeding trial and related intervention 
studies was that most of the intervention studies advised their subjects to restrict their 
energy intake [30, 82, 114], while we aimed to keep our subjects in energy balance 
during the trial. The recommended energy restriction resulted in weight loss in both 
the Mediterranean group and the control group in these studies. Therefore, they could 
not disentangle diet and weight loss effects. Two intervention studies aimed to maintain 
body weight during the study [31, 32, 60]. However, in the study by Ambring et al. 
a small but significant weight loss occurred during the study (mean weight loss (sd) 
-0.7 kg (1.1)) [32]. In the PREDIMED study [31, 60], no significant change in body 
weight occurred. In this study, subjects in the two Mediterranean groups were advised 
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to consume a Mediterranean diet and were provided with supplemental products: either 
virgin olive oil or nuts. Although subjects in the control group were advised to consume 
a low fat diet, they also seem to have eaten according to a Mediterranean type of diet as 
they were living in a Mediterranean region in which olive oil consumption was high. 
Therefore, the effects found in this study might rather be due to the supplemented 
products (virgin olive oil or nuts) than to a Mediterranean diet as a whole.
In our intervention study, we aimed to overcome these shortcomings by introducing a 
large contrast between the Mediterranean diet and the high SFA-diet. To achieve this 
we replaced SFA with MUFA and we introduced other Mediterranean components: 
fatty fish (3 servings/week), unrefined-grain products, nuts (15 g/day), legumes (40 g/
day), and red wine (1 glass/day), which were exclusively provided to the Mediterranean 
diet group. In addition, we controlled dietary intake by providing for 90% of the 
daily energy needs of our subjects. Although we tried to keep the subjects in energy 
balance during the trial, a small weight loss occurred (high SFA-diet: -1.5 kg (sd 1.4), 
high MUFA-diet: -0.6 kg (sd 1.4), Mediterranean diet: -1.4 kg (sd 1.8)). Between the 
intervention groups, the weight loss was not significantly different and adjustment of 
our analysis for weight loss did not change our conclusions. 
A Mediterranean diet and the metabolic syndrome
Our observational studies showed no significant association between a Mediterranean 
diet and the metabolic syndrome. However, the results of the SENECA study suggested 
that the prevalence of the metabolic syndrome was lower in subjects with good 
adherence to a Mediterranean diet compared with subjects with poor adherence. 
We could not confirm this finding ourselves, as we did not study the effects of a 
Mediterranean diet on the metabolic syndrome in our intervention study. Yet, two 
other intervention studies do underpin SENECA’s observations, by showing that 
a Mediterranean diet reduced the prevalence of the metabolic syndrome [30, 60]. 
Further support comes from observational studies that showed that subjects with good 
adherence to a Mediterranean diet were less likely to have the metabolic syndrome 
(OR 0.81, 95%CI 0.68; 0.98) [27] or that subjects with the highest adherence to a 
Mediterranean diet (Mediterranean diet score 6-9) had lower incidence rates of the 
metabolic syndrome (OR 0.20, 95%CI 0.06; 0.63) compared with subjects with the 
lowest adherence (Mediterranean diet score 0-2) [28].
The findings of the CoDAM study do not support these inverse associations between 
a Mediterranean diet and the metabolic syndrome. This inconsistency between the 
SENECA study and the CoDAM study might be due to the differences in dietary cut-
off values used as explained before.
In conclusion, our findings in the SENECA study, strengthened by observational and 
intervention studies carried out by others, suggest that a Mediterranean diet may be 
associated with the metabolic syndrome.
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A Mediterranean diet and HDL-cholesterol concentrations, triglyceride 
concentrations and waist circumference
The SENECA study showed that subjects with good adherence to a Mediterranean 
diet had higher HDL-cholesterol and lower triglyceride concentrations than subjects 
with poor adherence. Furthermore, the SENECA study suggested an inverse 
association between a Mediterranean diet and waist circumference. The findings 
on HDL-cholesterol and triglyceride concentrations are in line with the findings of 
our intervention study. In addition, our study showed that the beneficial effect of a 
Mediterranean diet on HDL-cholesterol concentration is probably not due to the 
high MUFA content of the diet but to the other components of a Mediterranean diet. 
One of the Mediterranean components that is expected to increase HDL-cholesterol 
concentration is alcohol. However, we calculated that alcohol intake only accounted 
for 22% (0.02 mmol/L) of the observed increase in HDL-cholesterol concentration 
(0.09 mmol/L). Although the differential change in triglyceride concentrations was 
not significant between the Mediterranean diet and the high MUFA-diet (-0.05 
mmol/L, 95%CI -0.18; 0.08) and between the high MUFA-diet and the high SFA-diet 
(-0.12 mmol/L, 95%CI -0.25; 0.01), the difference between the Mediterranean diet 
and the high SFA-diet was significant (-0.17 mmol/L, 95%CI -0.30; -0.04). Also, the 
difference in triglyceride concentration between the Mediterranean diet and the high 
MUFA-diet was almost twice as large as the difference between the high MUFA-diet 
and the high SFA-diet. These findings suggest that the effect of a Mediterranean diet 
on triglyceride concentration may not only be due to its high MUFA content but also 
to the other components of a Mediterranean diet. However, we also cannot exclude 
the possibility that weight loss during our trial influenced HDL-cholesterol and 
triglyceride concentrations.
The findings on HDL-cholesterol and triglyceride concentrations of the SENECA study 
are in agreement with the beneficial effects found in our intervention study and with 
those found in other intervention studies. The increase in HDL-cholesterol observed 
in our study (0.09 mmol/L) was similar to the increase in HDL-cholesterol observed 
after a 12 week intervention with a Mediterranean diet supplemented with olive oil or 
nuts (0.08 mmol/L, 0.04 mmol/L respectively) [31] and to the increase after a 2 year 
intervention with a Mediterranean diet (0.08 mmol/L) [30] compared with the control 
diets. In addition, the decrease in triglyceride concentration observed in our study 
(-0.17 mmol/L) was similar to the decrease in triglyceride concentration observed 
after a 4 week intervention with a Mediterranean diet (-0.20 mmol/L) [32] and to the 
decrease after a 12 week intervention with a Mediterranean diet supplemented with 
nuts (-0.15 mmol/L) [31] and also with the decrease after a 2 year intervention with a 
Mediterranean diet (-0.21 mmol/L) [30] compared with the control diets. Furthermore, 
the inverse association between a Mediterranean diet and waist circumference 
suggested by the SENECA study is in line with a recent review that concluded that 
although inconsistency exists in the literature, the evidence points towards a possible 
role of the Mediterranean diet in preventing obesity [115].
The findings of the CoDAM study concerning HDL-cholesterol and triglyceride 
concentrations and waist circumference were neither in line with the findings of the 
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SENECA study nor with those emerging from the intervention study. Besides the 
already mentioned differences in dietary cut-off values, this inconsistency may be 
due to the difference in contrast between subjects with good and poor adherence to 
a Mediterranean diet specifically regarding the Mediterranean components ‘dairy 
products’ and ‘meat and poultry’. In the SENECA study, these two components of the 
Mediterranean diet score were the only components that were significantly associated 
with HDL-cholesterol, triglycerides or waist circumference. However, in the CoDAM 
study the mean intake of these two components did not differ significantly between 
subjects with good adherence to a Mediterranean diet (dairy products 294 g/day (sd 
242), meat and poultry 128 g/day (sd 61)) and subjects with poor adherence (dairy 
products 327 g/day (sd 230), meat and poultry 135 g/day (sd 57)). As a result, the 
contrast between subjects with good and poor adherence to a Mediterranean diet may 
not have been sufficient to show an association with HDL-cholesterol and triglyceride 
concentrations or waist circumference in the CoDAM study.
In conclusion, our results together with the findings of other studies support the 
hypothesis that a Mediterranean diet beneficially affects HDL-cholesterol and 
triglyceride concentrations and suggest a beneficial effect on abdominal obesity. 
A Mediterranean diet and glucose metabolism
Our studies did not find support for the hypothesis that a Mediterranean diet affects 
glucose metabolism. Especially for our intervention study, this might seem surprising 
as we designed our trial to include subjects who were likely to be insulin resistant 
by involving subjects with mild abdominal obesity. However, the mean insulin 
concentration of our subjects indicated that they were on average not insulin resistant. 
If baseline levels of insulin would have been higher, insulin levels might have decreased 
more in response to a Mediterranean diet.
Moreover, our trial was powered to detect a difference in insulin concentration of at 
least 8.5 pmol/L between the intervention groups. However, we did not observe such 
a large difference in our study. Therefore, the effect of a Mediterranean diet, if present, 
may be smaller than this 8.5 pmol/L.
Other intervention studies did show that a Mediterranean diet improved glucose 
metabolism compared with the control diet in high-risk subjects [30, 31] but not in 
healthy subjects [32]. These findings support our idea that in particular subjects with 
high risk might be responsive to a Mediterranean diet. However, in the intervention 
study of Esposito et al. [30], the decrease in insulin concentration of 27 pmol/L induced 
by a Mediterranean diet may be partly due to weight loss and may therefore represent an 
indirect effect. The PREDIMED study did study the direct effect of a Mediterranean diet 
[31] and showed that a Mediterranean diet supplemented with virgin olive oil decreased 
insulin concentration by 17 pmol/L and that a Mediterranean diet supplemented with 
nuts reduced insulin concentration by 20 pmol/L compared with the control diet. 
However, as mentioned before, the differences in insulin concentrations observed in 
their study may largely be due to the supplemented products (virgin olive oil or nuts) 
rather than to a Mediterranean diet as a whole.
One observational study [29] supports our idea that subjects with high risk might 
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be more responsive to a Mediterranean diet than healthy subjects, as it did not find 
an association between a Mediterranean diet and glucose concentration in a healthy 
Spanish population. However, findings of two other observational studies in healthy 
Greek and Italian populations do not support our idea, as one of them found an inverse 
association between a Mediterranean diet and glucose concentration [33] and the other 
one even found a positive association in women [116]. In addition, the findings of our 
observational studies did not show a beneficial association between a Mediterranean 
diet and glucose metabolism in neither the high-risk subjects of the CoDAM study 
nor in the apparently healthy elderly subjects of the SENECA study. 
In conclusion, although we did not find support for the hypothesis that a Mediterranean 
diet affects glucose metabolism, we cannot exclude the possibility that an effect 
exists.
A Mediterranean diet and blood pressure
Only in the CoDAM study, we could study the association between a Mediterranean 
diet and blood pressure. However, we did not find an association. This result is similar 
to the results of two observational studies [116, 117]. However, other observational 
studies showed that a Mediterranean diet was associated with a reduced likelihood of 
having hypertension [29, 118] or a decrease in blood pressure levels [119]. In addition, 
intervention studies showed that a Mediterranean diet reduced blood pressure [30, 
31, 60].
In conclusion, although we did not find an association between a Mediterranean diet 
and blood pressure in the CoDAM study, the results of other studies indicate that a 
Mediterranean diet might reduce blood pressure.
General conclusion
The results of our studies together with the results of other studies support the 
hypothesis that a Mediterranean diet has a beneficial effect on two characteristics of the 
metabolic syndrome: HDL-cholesterol and triglyceride concentrations, and probably 
also on a third characteristic of the metabolic syndrome: waist circumference. Although 
our results do not support the hypothesis that a Mediterranean diet improves the other 
characteristics of the metabolic syndrome (glucose metabolism and blood pressure), 
we cannot exclude the possibility that a beneficial effect exists as well.
As this thesis finds support for a favourable effect on two out of five characteristics of 
the metabolic syndrome and also suggests a favourable effect on a third characteristic, 
we conclude that a Mediterranean diet may help to prevent the metabolic syndrome, 
and consequently diabetes mellitus type 2 and cardiovascular disease. 
Future studies and public health implications
Our results together with results of other studies indicate that there is an association 
between a Mediterranean diet and the metabolic syndrome. However, there is limited 
evidence available from prospective cohort studies. Therefore, there is still a need for 
such studies. As in our observational studies, the method used to assess adherence 
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to a Mediterranean diet should receive due attention. The use of median intakes of 
Mediterranean components as cut-off values in the Mediterranean diet score makes 
this score a useful tool to distinguish between subjects with good and poor adherence 
to a Mediterranean diet in any population. Especially in Northern European countries, 
a drawback of this method is that the cut-off values may not represent a traditional 
Mediterranean diet and that it does not take into account the full range of intake of 
the Mediterranean components due to the dichotomisation of the components. An 
alternative is to study the effect of a Mediterranean diet on the metabolic syndrome in 
further intervention studies, in which special attention should be given to abdominal 
obesity and glucose metabolism. Our results and the findings of others suggest that 
a Mediterranean diet may have a beneficial effect on abdominal obesity. However, as 
there is inconsistency in the evidence, further studies in this area are needed [115]. In 
these studies, also the indirect effect of a Mediterranean diet on glucose metabolism 
(mediated by weight loss) could be studied.
However, the direct effect of a Mediterranean diet on glucose metabolism can only be 
shown in a study where no weight loss occurs. This implies that subjects should be kept 
in energy balance for the full duration of the study. Therefore, a completely controlled-
feeding trial would be an appropriate study design. The effects of a Mediterranean 
diet could then be compared with the effects of a Western style diet. In the power 
calculations, an effect size smaller than 8.5 pmol/L between the intervention groups 
should be taken into account. As we do not know yet whether high-risk subjects would 
be more responsive to a Mediterranean diet than healthy subjects, this intervention 
study should be performed in both populations. Such intervention studies will not only 
provide information about the effects of a Mediterranean diet on glucose metabolism 
but will, if extended with metabolic in-depth studies, also provide insight in the 
underlying mechanism. 
As a Mediterranean diet may help preventing the metabolic syndrome (this thesis), 
reducing the incidence of diabetes mellitus type 2 [61] and reducing mortality rates 
from cardio vascular disease [22], we favour public health measures that stimulate 
eating a more Mediterranean type of diet.
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The metabolic syndrome 
The metabolic syndrome refers to a clustering of risk factors including abdominal 
obesity, hyperglycaemia, low HDL-cholesterol, hypertriglyceridaemia, and 
hypertension and is a risk factor for diabetes mellitus type 2 and cardiovascular disease. 
According to the definition of the National Cholesterol Education Program 2001 
(NCEP), the metabolic syndrome is present if at least three out of five characteristics 
are present: abdominal obesity (waist circumference >102 cm for men and >88 cm for 
women), hyperglycaemia (glucose concentration ≥6.1 mmol/L), low HDL-cholesterol 
concentration (HDL-cholesterol concentration <1.04 mmol/L for men and <1.29 
mmol/L for women), hypertriglyceridaemia (triglyceride concentration ≥1.7 mmol), 
and hypertension (systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 
mmHg). According to our own observations, the prevalence of the metabolic syndrome 
in the Netherlands was 14% in adults below 60 years of age in the 1990s (chapter 
2). When this prevalence is extrapolated to the Dutch population, it corresponds to 
approximately 1 million persons with the metabolic syndrome in the 1990s.
Mediterranean diet 
Underlying risk factors for the metabolic syndrome are physical inactivity and an 
unhealthy diet. Therefore, lifestyle changes may play an important role in the prevention 
of the metabolic syndrome. A Mediterranean diet has been considered a healthy diet 
as it has been associated with a reduced risk of mortality. A Mediterranean diet might 
also have favourable effects on the metabolic syndrome. A Mediterranean diet refers 
to a dietary pattern as consumed in countries of the Mediterranean region during the 
early 1960s. Characteristics of a Mediterranean diet are use of olive oil as the main 
added lipid, abundant use of plant foods (fruits, vegetables, cereals, legumes, nuts, and 
seeds), moderate intake of fish and wine, and low to moderate consumption of dairy 
products and meat and poultry. In this thesis, we studied whether a Mediterranean 
diet favourably affects the metabolic syndrome.
Observational studies 
We studied whether a Mediterranean diet is associated with the metabolic syndrome 
in two observational studies. First we analysed this association in a European elderly 
population using baseline data of the Survey in Europe on Nutrition and the Elderly, 
a Concerted Action (SENECA) (chapter 3). The SENECA study was carried out in 
1988-1989 and included 627 men and 631 women, aged between 70 and 76 years 
from 10 European countries. Adherence to a Mediterranean diet was assessed by the 
Mediterranean diet score that was developed by Trichopoulou et al. (MDS, range 0 
through 9). Although not statistically significant, elderly subjects with good adherence 
to a Mediterranean diet (MDS >4 (median)) had a lower prevalence of the metabolic 
syndrome (prevalence ratio 0.81, 95%CI 0.65; 1.03) and tended to have smaller waist 
circumference (-1.1 cm, 95%CI -2.4; 0.3) than elderly subjects with poor adherence. 
Good adherence to a Mediterranean diet was associated with higher HDL-cholesterol 
(0.05 mmol/L, 95%CI 0.00; 0.10) and lower triglyceride concentrations (-0.12 mmol/L, 
95%CI -0.24; 0.00) but not with measures of insulin sensitivity. These results implicate 
that the prevalence of the metabolic syndrome is lower in elderly people with good 
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adherence to a Mediterranean diet.
Second, we analysed the association between a Mediterranean diet and the metabolic 
syndrome in the baseline data of the Cohort study on Diabetes and Atherosclerosis 
Maastricht (CoDAM) in the Netherlands. The CoDAM study was carried out in 1999-
2000 and included 450 subjects (275 healthy subjects with normal glucose tolerance, 111 
subjects with impaired glucose regulation and 64 subjects with diabetes mellitus type 
2). Adherence to a Mediterranean diet was assessed by the Mediterranean diet score 
(MDS, range 0 through 9). In this study, a Mediterranean diet was not associated with 
the prevalence of the metabolic syndrome (prevalence ratio 1.0, 95%CI 0.8; 1.2).
Intervention study 
In addition, we conducted a controlled-feeding trial to compare the effects of replacing 
a high saturated fatty acids (SFA) diet with a high monounsaturated fatty acids 
(MUFA) diet or a Mediterranean diet on characteristics of the metabolic syndrome: 
HDL-cholesterol and triglyceride concentrations, and glucose metabolism (glucose 
concentration and insulin sensitivity) (chapters 5 and 6). We included 60 subjects 
(40-65 years) with mild abdominal obesity. Subjects were provided with 90% of their 
daily energy needs. After a two week run-in diet high in SFA (19% of total energy 
intake (energy-%)), subjects were allocated to a high MUFA-diet (20 energy-%), 
a Mediterranean diet (MUFA 21 energy-%), or the high SFA-diet, for eight weeks. 
Replacing a high SFA-diet with a high MUFA or a Mediterranean diet did not affect 
insulin sensitivity, but decreased total cholesterol, LDL-cholesterol and triglyceride 
concentrations. In addition, this trial showed that a Mediterranean diet increased 
HDL-cholesterol more than the diet high in MUFA did.
General conclusion 
The results of our studies together with the results of other studies support the 
hypothesis that a Mediterranean diet has a beneficial effect on two characteristics of the 
metabolic syndrome: HDL-cholesterol and triglyceride concentrations, and probably 
also on a third characteristic of the metabolic syndrome: waist circumference. 
As this thesis finds support for a favourable effect on two out of five characteristics of 
the metabolic syndrome and also suggests a favourable effect on a third characteristic, 
we conclude that a Mediterranean diet may help to prevent the metabolic syndrome, 
and consequently diabetes mellitus type 2 and cardiovascular disease.
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Metabool syndroom 
Het metabool syndroom is een belangrijke risicofactor voor diabetes mellitus type 
2 en hart- en vaatziekten. Het metabool syndroom refereert aan een clustering van 
risicofactoren gerelateerd aan abdominale obesitas, hyperglycemie, dyslipidemie en 
hypertensie. Volgens de definitie van het National Cholesterol Education Program 
2001 is het metabool syndroom aanwezig wanneer aan minimaal drie van de volgende 
criteria is voldaan: abdominale obesitas (middelomvang >102 cm voor mannen en 
>88 cm voor vrouwen), hyperglycemie (nuchtere glucoseconcentratie ≥6.1 mmol/L), 
HDL-cholesterolconcentratie <1.04 mmol/L voor mannen en <1.29 mmol/L voor 
vrouwen, hypertriglyceridemie (triglyceridenconcentratie ≥1.7 mmol/L), hypertensie 
(systolische bloeddruk ≥130 mmHg en/of diastolische bloeddruk ≥85 mmHg). Uit 
ons onderzoek bleek dat de prevalentie van het metabool syndroom in Nederland in 
personen jonger dan 60 jaar 14% was (hoofdstuk 2). Wanneer dit percentage wordt 
geëxtrapoleerd naar de Nederlandse bevolking komt dit overeen met circa 1 miljoen 
personen met het metabool syndroom in de jaren ’90.
Mediterrane voeding 
Onderliggende risicofactoren voor het metabool syndroom zijn onder meer weinig 
lichamelijke activiteit en een ongezonde voeding. Veranderingen in voedingsgewoonten 
kunnen een rol spelen bij de preventie van het metabool syndroom. Van een voeding 
volgens een Mediterraan patroon wordt bijvoorbeeld verwacht dat deze gunstige 
effecten zou kunnen hebben op het metabool syndroom. Een Mediterrane voeding 
wordt gekarakteriseerd door ruimschoots gebruik van olijfolie, hoge consumptie van 
groente, fruit, graanproducten, peulvruchten, noten en zaden, matige consumptie 
van vis en wijn en lage consumptie van zuivelproducten, vlees en gevogelte. In dit 
proefschrift hebben we onderzocht of een Mediterrane voeding een gunstig effect 
heeft op het metabool syndroom.
Observationele studies 
In twee observationele studies hebben we de relatie tussen het eten volgens een 
Mediterraan patroon en het metabool syndroom onderzocht. De eerste studie 
waarin we dit zijn nagegaan is de SENECA studie (hoofdstuk 3). SENECA is een 
acroniem voor ‘Survey in Europe on Nutrition and the Elderly, a Concerted Action’. 
De SENECA studie is een studie onder ouderen tussen de 70 en 76 jaar uit 10 
Europese landen. De data van de SENECA studie zijn verzameld in 1988 en 1989. 
De Mediterrane voedingsscore (MVS) die ontwikkeld is door Trichopoulou et al. is 
gebruikt om vast te stellen of er volgens een Mediterraan patroon werd gegeten. Uit 
deze studie bleek dat ouderen die volgens een Mediterraan patroon aten (MVS >4) 
minder hoge HDL-cholesterolconcentraties (0.05 mmol/L, 95%CI 0.00; 0.10) en lagere 
triglyceridenconcentraties (-0.12 mmol/L, 95%CI -0.24; 0.00) hadden dan ouderen 
die niet Mediterraan aten. Tevens leek het erop dat ouderen die Mediterraan aten 
minder vaak het metabool syndroom hadden (prevalentieratio 0.81, 95%CI 0.65; 
1.03) en een smallere middelomvang hadden (-1.1 cm, 95%CI -2.4; 0.3) dan ouderen 
die niet Mediterraan aten. De laatste twee bevindingen waren echter niet statistisch 
significant. 
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De tweede studie waarin we de relatie tussen het eten volgens een Mediterraan patroon 
en het metabool syndroom hebben onderzocht is de CoDAM studie (hoofdstuk 
4). CoDAM is een acroniem voor ‘Cohort study on Diabetes and Atherosclerosis 
Maastricht’. Deze studie is uitgevoerd in Maastricht in 1999 en 2000 en omvatte 450 
deelnemers. Van deze deelnemers hadden 64 diabetes mellitus type 2, 11 een verstoorde 
glucosetolerantie en 275 een normale glucose tolerantie. In deze studie bleek geen 
duidelijk verband te bestaan tussen de mate waarin de deelnemers een Mediterrane 
voeding gebruikten en de prevalentie van het metabool syndroom (prevalentieratio 
1.0, 95%CI 0.8; 1.2).
Voedingsproef 
Vervolgens hebben we onderzocht wat het effect is van het vervangen van een voeding 
met veel verzadigd vet (VV) door een voeding met veel enkelvoudig onverzadigd vet 
(EOV) of een Mediterrane voeding op enkele componenten van het metabool syndroom. 
Dit gebeurde in een 10 weken durende volledig gecontroleerde voedingsproef met 60 
deelnemers tussen de 40 en 65 jaar (hoofdstukken 5 en 6). De deelnemers aan deze 
voedingsproef kregen 90% van hun voeding verstrekt. Na een inloopperiode van 
2 weken werden ze verdeeld over drie groepen om vervolgens gedurende 8 weken 
een ‘westerse’ voeding rijk aan verzadigd vet (VV 19% van de totale energie-inname 
(energie-%)), een voeding rijk aan enkelvoudig onverzadigd vet (EOV 20 energie-%), 
of een Mediterrane voeding (EOV 21 energie-%) te gebruiken. De voeding rijk aan 
enkelvoudig onverzadigd vet en de Mediterrane voeding verhoogden de gevoeligheid 
voor insuline niet ten opzichte van de ‘westerse’ voeding. De voeding rijk aan 
enkelvoudig onverzadigd vet en de Mediterrane voeding verlaagden de cholesterol- en 
triglyceridenconcentraties. Verder zagen we dat de Mediterrane voeding de HDL-
cholesterolconcentratie verhoogde terwijl dit niet het geval was voor de voeding rijk 
aan enkelvoudig onverzadigd vet.
Conclusie 
Onze onderzoeksresultaten samen met de onderzoeksresultaten van anderen, laten zien 
dat een Mediterrane voeding een gunstig effect heeft op twee van de vijf componenten 
van het metabool syndroom namelijk HDL-cholesterol- en triglyceridenconcentraties. 
Verder suggereren onze resultaten uit de SENECA studie dat een Mediterrane voeding 
ook een gunstig effect heeft op een derde component van het metabool syndroom, 
namelijk de middelomvang. We kunnen daarom concluderen dat een Mediterrane 
voeding kan helpen om het metabool syndroom te voorkomen en daarmee het risico 
op het krijgen van diabetes mellitus type 2 en hart- en vaatziekten te verlagen.
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